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1. Introduction 
The tankyrases (PARP-5a / TNKS-1 / ARTD5 and PARP-5b / 
TNKS-2 / ARTD6) are members of the poly(ADP-ribose)poly-
merase (PARP) superfamily of enzymes.
1
 Considerable recent 
interest has been expressed in these enzymes,
2-10
 in view of their 
roles at the chromosomal telomeres, at the mitotic spindle and in 
signalling pathways. In common with other PARPs, the tankyr-
ases transfer ADP-ribose units from substrate NAD
+
 to build 
poly(ADP-ribose)polymers on target proteins. TNKS-1 poly-
(ADP-ribosyl)ates TRF1 at the telomere, causing it to detach 
from the telomere and become ubiquitinylated and targeted for 
destruction.
11,12
 This exposes the telomeric DNA, allowing access 
by the telomerase complex. Thus TNKS-1 activity is a positive 
regulator of telomere length. Tankyrase activity is also critical for 
the correct functioning of the mitotic spindle, where its protein 
target is NuMA.
13
 TNKS-1 is also a component of the wnt signal-
ling system,
9,14
 where it modifies axin. This leads to ubiquitinyl-
ation and destruction of the poly(ADPr)-axin, increasing levels of 
-catenin and suppressing phosphorylated -catenin. The net 
effect of this activity is a proliferative signal in the nucleus. The 
isoform TNKS-2 can substitute for TNKS-1 in many of these 
intracellular activities.
11,15,16
 
Tankyrases are over-expressed in several clinical cancers and 
cancer cell lines, including mammary
17
 and colorectal carcin-
omas,
18
 chronic myeloid leukaemia,
19
 and tumours in brain,
20
 
stomach
21
 and bladder.
22
 This over-expression indicates critical 
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The tankyrases are members of the PARP superfamily; they poly(ADP-ribosyl)ate their target 
proteins using NAD
+
 as a source of electrophilic ADP-ribosyl units. The three principal protein 
substrates of the tankyrases (TRF1, NuMA and axin) are involved in replication of cancer cells; 
thus inhibitors of the tankyrases may have anticancer activity. Using structure-based drug design 
and by analogy with known 3-arylisoquinolin-1-one and 2-arylquinazolin-4-one inhibitors, 
series of arylnaphthyridinones, arylpyridinopyrimidinones and their tetrahydro-derivatives were 
synthesised and evaluated in vitro. 7-Aryl-1,6-naphthyridin-5-ones, 3-aryl-2,6-naphthyridin-1-
ones and 3-aryl-2,7-naphthyridin-1-ones were prepared by acid-catalysed cyclisation of the cor-
responding arylethynylpyridinenitriles or reaction of bromopyridinecarboxylic acids with -
diketones, followed by treatment with NH3. The 7-aryl-1,6-naphthyridin-5-ones were methylated 
at 1-N and reduced to 7-aryl-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-ones. Cu-catalysed 
reaction of benzamidines with bromopyridinecarboxylic acids furnished 2-arylpyrido[2,3-d]pyr-
imidin-4-ones. Condensation of benzamidines with methyl 1-benzyl-4-oxopiperidine-3-
carboxylate and deprotection gave 2-aryl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-ones, aza 
analogues of the known inhibitor XAV939. Introduction of the ring-N in the 
arylnaphthyridinones and the arylpyridopyrimidinones caused >1000-fold loss in activity, com-
pared with their carbocyclic isoquinolinone and quinazolinone analogues. However, the 7-aryl-
1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-ones showed excellent inhibition of the tank-
yrases, with some examples having IC50 = 2 nM. One compound (7-(4-bromophenyl)-1-methyl-
1,2,3,4-tetrahydro-1,6-naphthyridin-5-one) showed 70-fold selectivity for inhibition of 
tankyrase-2 vs. tankyrase-1. The mode of binding was explored through crystal structures of 
inhibitors in complex with tankyrase-2. © 2014 Elsevier Ltd. All rights reserved. 
 
Keywords: 
Tankyrase 
TNKS 
Naphthyridinone 
7-Aryl-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-
5-one 
Crystal structure 
 
roles for the tankyrases in tumours; they were proposed as thera-
peutic targets as long ago as 2006.
23
 Their recent discovery
9
 as 
components of the proliferative wnt signalling pathway confirms 
this potential. Indeed, one tankyrase inhibitor has shown activity 
in an APC-mutant mouse model of colon cancer
24 
and has been 
shown to cause
 
apoptosis in neuroblastoma cells.
8
 The time is, 
therefore, ripe to explore the structure-based design and develop-
ment of potent and selective inhibitors of the tankyrases. 
The reported inhibitors of the tankyrases fall into two classes: 
those that bind in the nicotinamide-binding site as mimics of nic-
otinamide and those which are bound at other sites, including the 
adenine-binding site. Some recent inhibitors have been designed 
to occupy both sites simultaneously. 
Examination of the crystal structure of the prototype inhibitor 
XAV939 1 (Figure 1) bound into TNKS-2 reveals that the lactam 
makes H-bonds with the carbonyl and NH of Gly
1032
 and the 
side-chain alcohol of Ser
1068
.
25
 There is also some evidence for -
stacking with Tyr
1071
. The side-chain 4-trifluoromethylphenyl 
projects into an adjacent hydrophobic cavity, forming a -stack 
with Tyr
1050
 and hydrophobic interactions with Pro
1034
, Phe
1035 
and Ile
1075
.
4
 We have reported that 2-aryl-8-methylquinazolin-4-
ones 2 and related 3,4-dihydroquinazolinones also inhibit the 
tankyrases strongly, with IC50 values slightly higher than those of 
1.
4,26
 Molecular modelling studies indicated that the mode of 
binding of 2 is similar to that of 1, with the aryl group projecting 
into the hydrophobic cavity.
4
 Very recently, we disclosed a large 
series of 5-substituted 3-arylisoquinolin-1-ones 3, some of which 
(e.g. 3: R
4’
 = R
5
 = Me) were more potent than 1. Water-soluble 
tertiary amine analogues (e.g. 3: R
4’
 = CH2NMe2, R
5
 = Me) 
retained potency.
3
 A crystal structure of 3 (R
4’
 = Cl, R
5
 = OMe) 
in complex with TNKS-2 (PDB code 4UVY) confirmed the 
mode of binding, with the lactam carbonyl oxygen accepting H-
bonds from Gly
1032
 and Ser
1068 
and the lactam N-H donating an 
H-bond to the carbonyl of
 
Gly
1032
.
3
 The chlorophenyl unit occup-
ies the hydrophobic cavity, with the chlorine located at the entr-
ance to a narrow tunnel leading to the exterior. Extensions at R
4’
 
project deep into this tunnel. Although the lactam carbonyl and 
the phenyl in the hydrophobic pocket are essential for binding, 
the N-H of the lactam is less important, in that flavones such as 4 
are active.
27,28
 The [1,2,4]triazolo[4,3-b]pyridazine 5 has also 
been shown crystallographically to bind in the nicotinamide-
binding pocket, with 1-N making a H-bond to N-H of Gly
1032
, 2-
N making a H-bond with OH of Ser
1068
 and the exocyclic N-H 
bonding with the C=O of Gly
1032
; the phenol occupies the hydro-
phobic cavity.
2
 Curiously, this compound is selective for inhibit-
ion of TNKS-1 (IC50 = 12 nM) vs. TNKS-2 (IC50 = 200 nM). 
IWR1 6 binds solely at the nearby adenosine-binding site,
29
 whe-
reas 7
7
 and 8
10
 occupy both the nicotinamide-bind site and the 
adenosine-binding site. 
2. Results & Discussion 
2.1. Design of inhibitors 
In the light of the potency and selectivity of our series of 3-
arylisoquinolin-1-ones 3
3
 and 2-arylquinazolin-4-ones 2
4
 for in-
hibition of the tankyrases, we sought to extend the structure-act-
ivity relationships (SARs) into aza analogues. Figure 2 shows the 
structures of these candidate inhibitors. Introducing a nitrogen 
into the carbocyclic ring of 3 (in naphthyridinones 9-11) will 
have two potential effects, electron-deficiency in the bicycle and 
weak basicity or H-bonding involving the N-lone pair. Para-sub-
stitution was found to be optimum in the phenyl rings of 2
4
 and 
3
3
; thus only para-substituted phenyl rings were targeted in the 
present work. The lactam of 9-11 was expected to form the usual 
H-bonds with Ser
1068
 and Gly
1032
 (TNKS-2 numbering), mimick-
ing the nicotinamide of NAD
+
. The phenyl ring should occupy 
the adjacent hydrophobic cavity, making hydrophobic and -
stacking interactions therein, with the para-substituent projecting 
into the distal tunnel (Figure 3 shows a cartoon of the binding 
pocket). In the 2-arylquinazolin-4-one series 2, a small substit-
uent, e.g. Me, at the 8-position slightly improved potency.
3
 Simil-
arly, 5-methyl-3-arylisoquinolin-1-ones (3: R
5
 = Me) generally 
had higher activity than their 5-fluoro (3: R
5
 = F), 5-hydroxy (3: 
R
5
 = OH) or 5-amino- (3: R
5
 = NH2) counterparts.
4
 Thus we des-
igned the 1-methyl-naphthyridin-5-ones 12 with the N-methyl 
occupying the same pocket in the enzyme. Of course, this makes 
major changes in electron-distribution in the bicyclic core and 12 
are cationic. Similarly, the N-oxide in 13 would occupy the same 
pocket but without overall charge. The arylpyridopyrimidinones 
14-16 are aza analogues of the active quinazolinones 3. As for 9-
11, the additional nitrogen may make H-bonds. 
Unlike PARP-1, the nicotinamide-binding site of the tankyr-
ases can accommodate a (partly) saturated ring mimicking the 
pyridinium of NAD
+
, as shown by the activity of 1. Thus we 
chose to explore the tetrahydro analogues 17 and 18. In the 7-
aryl-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-ones 17, the 
left ring has three contiguous sp
2
-hybridised atoms (presumably 
coplanar with the pyridinone) and three sp
3
 methylenes. Thus the 
conformation may be slightly different to that of 1 but the N-Me 
should occupy the same space as the 5-Me in 3 (R
5
 = Me) and the 
8-Me in 2. The tetrahydropyridopyrimidinones 18 (especially 
18d, R = CF3) are strict analogues of 1, where the neutral lipoph-
ilic sulfur is replaced by a secondary amine. This amine should 
be protonated at physiological pH, so 18 should have the same 
conformation as 1 but will test the tolerance of the binding 
pocket to positive charge. 
Figure 1. Structures of reported inhibitors of the tankyrases. 
2.2. Chemical synthesis 
The initial targets for synthesis were the 7-aryl-1,6-naphthyr-
idin-5-ones 9, the 3-aryl-2,7-naphthyridin-1-ones 10 and the 3-
aryl-2,6-naphthyridin-1-ones 11. Wibberley prepared 9a in 1.6% 
yield from ethyl 2-methylpyridine-3-carboxylate and benzalde-
hyde, via 26a.
30
 Reaction of 2-(2-phenyl-2-oxoethyl)pyridine-3-
carboxylic acid with ammonia gives 9a directly in 80% yield.
31
 
Nishiwaki et al. examined cyclisation of 2-phenylethynyl-3-
cyanopyridine 25a under various conditions.
32
 Under basic cond-
itions, the principal product arose from hydration / 5-exo-dig cyc-
lisation, whereas strong acid furnished an equimolar mixture of 
26a and 9a from 6-endo-dig cyclisation of the intermediate 
amide. By contrast, Pt-catalysed cyclisation of 25a is reported to 
afford a mixture of 9a and 5-ethoxy-7-phenyl-1,6-naphthyridine 
in moderate yields.
33
 This method also provides 10a in low yield. 
Isomer 11a has been prepared in low yield by debenzylation of 1-
benzyl-4-phenacylpyridine-3-carboxamide.
35
 This route was dev-
eloped by N-benzylation off nicotinamide. Riessert attack of 
acetophenone enolate at the 4-position, acid-catalysed cyclisation 
and debenzylation yields 11a.
35
 3-Phenyl-2,6-naphthyridin-1-one 
10a was formed in poor yield by a curious route involving treat-
ment of dimethyl 2-(4-methoxycarbonylpyridin-3-yl)malonate 
with NaCl in DMSO at high temperature, followed by reaction 
with ammonia.
36 
Of these routes, we selected the acid-catalysed cyclisation of 
arylethynyl-cyanopyridines 25, 28, 35 (Scheme 1), as the divers-
ity in the aryl group would be introduced through diversity in the 
starting arylethynes, many of which are commercially available 
or readily accessible synthetically. Arylethynes 21c-e,g,h, which 
are not economically commercially available, were obtained by 
Sonogashira coupling of the corresponding iodoarenes 19c-e,g,h 
with trimethylsilylethyne to give 20c-e,g,h, followed by desilyl-
ation. The phenolic OH of 4-iodophenol had earlier been masked 
with benzyl, using benzyl bromide and caesium carbonate in 
DMF, giving 19h. Similar coupling of 4-bromopyridine 22 with 
trimethylsilylethyne and subsequent desilylation afforded 4-eth-
ynylpyridine 21l in moderate yield, via intermediate 20l. 
Sonogashira coupling of the alkynes 21a-e,g,h,l with appropriate 
halopyridinenitriles was then investigated. Coupling of the alk-
ynes with 2-chloro-3-cyanopyridine 23 led to the key intermed-
iates 25 in low yields, despite activation of the chloroarene by the 
adjacent ring-N and the electron-withdrawing nitrile. This par-
allels our experience with Suzuki couplings to 3-chloroisoquinol-
ines.
3
 The poor yield was addressed in two ways. Firstly, 1,4-di-
arylbutadiynes were observed as major by-products, arising from 
oxidative Glaser homocoupling of the arylethynes.
37,38
 This was 
addressed by using an excess of the alkyne (wasteful) or by add-
ing sodium ascorbate to the reaction mixture as an antioxidant. 
Addition of sodium ascorbate also led to higher yields in some of 
the couplings of 19 and 22 with trimethylsilylethyne. Also effect-
ive in raising the yields of 25 was replacement of the 2-chloro-
pyridine 23 with the corresponding bromopyridine 24. This educt 
was prepared by acetolysis of 23 with acetic acid and hydrolysis 
of the intermediate 2-acetoxy-3-cyanopyridine in boiling aqueous 
THF under neutral conditions to give 3-cyanopyridin-2-one. Con-
ventional reagents (e.g. POBr3, PBr5) failed to give 24 but reac-
tion with Bu4NBr and P2O5 in toluene gave the bromopyridine in 
excellent overall yield. This 2-bromopyridine coupled with the 
range of arylethynes in moderate-to-good yields to give 25a-
e,g,h,l, catalysed by (Ph3P)2PdCl2. Aqueous acid-catalysed cyc-
lisation proceeded exclusively in the 6-endo-dig mode, affording 
mixtures of the 7-arylpyrano[4,3-b]pyridin-5-ones 26 and the 7-
aryl-1,6-naphthyridin-5-ones 9, from initial hydration to the car-
boxamide and trapping of the electrophile derived from the alk-
yne with either the oxygen or the nitrogen, respectively, of the 
amide. In many cases, these mixtures were separable with diffic-
ulty and 26 could be converted into 9 by treatment with ammonia 
in 2-methoxyethanol under pressure. However, it was more con-
venient to treat the mixtures directly with ammonia to afford 
good yields of 9. The benzyl protection of 25h was lost during 
the treatment with acid, forming 9i directly. 
Methylation of 9a-e,g at 1-N was achieved with iodomethane 
in DMF, affording 12a-e,g. The location of the methyl at 1-N 
was confirmed by HMBC correlations from NCH3 to 2-C and 
from 2-H to NCH3 and, in some cases, by nOe experiments. 
Interestingly, 9g, carrying a primary aniline, was only methylated 
at 1-N to give 12g. These quaternised naphthyridinium salts 12 
were targets in their own right but were also precursors of the 
tetrahydro analogues 17. Borane.pyridine complex has been rep-
orted
39
 to reduce naphthyridinium species but, in the case of 12, it 
was necessary to use formic acid as solvent for the reaction. The 
problem of decomposition of the borane complex by the acidic 
medium was overcome by adding the reductant in frequent small 
portions and 17a,c-f were obtained in low yields. 
The nucleophilicity of 1-N was also exploited in forming the 
N-oxides 13a,b from 9a,b, using anhydrous peroxytrifluoroacetic 
Tunnel
Hydrophobic cavity
Gly1032 / Ser1068
H-bond motif
3: R4’ = Cl, R5 = OMe
Figure 3. Cartoon showing the relative positions of binding motifs in the 
structures of the tankyrases, with the inhibitor 3 (R4’ = Cl, R5 = OMe) bound. 
Figure 2. Structures of arylnaphthyridinones 9-13, arylpyridopyrimidinones 
14-16, aryltetrahydronaphthyridinones 17 and aryltetrahydropyridopyrim-
idinones 18, designed as inhibitors of the tankyrases. R = H, Me, OMe, CF3, 
Cl, Br, NH2, OH, -CCPh, etc. 
acid generated in situ from urea.hydrogen peroxide complex and 
trifluoroacetic anhydride. We had previously used this system for 
the difficult N-oxidation of 8-cyanoquinoline to the N-oxide.
40
 
Although it was predictable that the oxidation had taken place at 
1-N, in the light of methylation occurring exclusively at this site, 
it was important to provide evidence for the regiochemical iden-
tity of target compounds 13a,b. In this case, the oxygen was loc-
ated by examination of the 
15
N NMR chemical shifts. After ass-
ignment using 
1
H-
15
N HMBC spectroscopy, the 
15
N chemical 
shifts for 9a were shown to be 1-N ( 278.87, HMBC correlation 
to 2-H and 8-H) and 6-N ( 124.89, HMBC correlation to 8-H 
only), whereas those for 13a were 1-N ( 252.76; HMBC correl-
ation to 2-H and 8-H) and 6-N ( 129.56; correlation to 8-H 
only). The marked change in chemical shift of 1-N upon oxidat-
ion, compared with the small change for 6-N, confirms that oxid-
ation took place at 1-N. 
Oxidation of 3-phenyl-3,4-dihydro-2,7-naphthyridin-1-one 
(from acid-catalysed cyclisation of 3-cyano-4-(2-phenylethenyl)-
pyridine) is reported to afford 11a.
41
 In the present work, the 3-
aryl-2,7-naphthyridin-1-ones 11 were approached through similar 
acid-catalysed cyclisations of arylethynylpyridinenitriles. 
Sonogashira couplings of 4-bromo-3-cyanopyridine 27 with the 
range of arylethynes 21a,c-e,g gave the required intermediates 
28a,c-e,g (Scheme 1) in moderate-to-good yields, in the presence 
of sodium ascorbate. Attempted couplings of 21b and 21l with 27 
failed, despite the activation of the 4-bromopyridine component 
by the ring-N. Cyclisation by reaction of 28a,c with hot aqueous 
sulfuric acid and treatment of the mixtures of 2,7-naphthyridin-1-
ones and pyrano[3,4-c]pyridin-1-ones with ammonia under press-
ure gave the required 3-aryl-2,7-naphthyridin-1-ones 11a,c. Cur-
iously, although the major components of the product mixtures 
from the cyclisations of 28a,c with sulfuric acid were the pyrano-
[3,4-c]pyridin-1-ones, the corresponding acid-catalysed reaction 
of the 4’-aminophenyl compound 28g gave only the naphthyrid-
inone 11g, obviating the need for treatment with ammonia. One 
example, 11a, was methylated at 7-N to provide the cation 29a 
but all attempts to reduce this to 3-phenyl-5,6,7,8-tetrahydro-2,7-
naphthyridin-1-one, by analogy with the preparation of 17, failed. 
Synthesis of synthesise 3-bromo-4-cyanopyridine 30 was 
required in approaching the 3-aryl-2,6-naphthyridin-1-ones 10a-e 
in the same way. Lithiation of 3-bromopyridine 30 with LDA and 
quench of the anion with carbon dioxide gave the 4-carboxylic 
acid 31 in low yield. Conversion into the amide 32 and dehydrat-
ion with POCl3 gave the required nitrile 34. Sonogashira coup-
Scheme 1. Synthetic approaches to target arylnaphthyridinones 9-11 by acid-catalysed cyclisation of arylethynylpyridinenitriles, N-oxidation to 13, methylation 
to 12, 29a, 36c and reduction to the 7-aryl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-ones 17. Reagents & conditions: i, BnBr, Cs2CO3, DMF; ii, Me3SiCCH, 
(Ph3P)2PdCl2, CuI, Na ascorbate, Et3N, THF, Ar, 40°C; iii, Bu4NF, THF; iv, AcOH, reflux; v, THF, H2O, reflux; vi, Bu4NBr, P2O5, PhMe, reflux; vii, 21, 
(Ph3P)2PdCl2, CuI, Na ascorbate, THF, Pr
i
2NH, Ar, 40°C; viii, aq. H2SO4 (9 M), reflux; ix, NH3, MeO(CH2)2OH, pressure, 100C; x, MeI, DMF; xi, Urea.H2O2, 
(F3CCO)2O, DMF, 0°C; xii, BH3.pyridine, HCO2H; xiii, LiNPr
i
2, solid CO2, THF, Ar, -78°C; xiv, EtO2CCl, Et3N, THF, 0ºC, then NH3; xv, POCl3, reflux. 
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lings attached the arylalkynes 21a-e, affording 35a-e. Cyclisation 
and treatment with ammonia furnished the targets 10a-c,e but the 
trifluoromethylphenylalkyne in 35d was insufficiently nucleo-
philic to react. Only one example, 10c, could be methylated at 6-
N (affording 36c) and this cation could not be reduced. 
Scheme 2 shows development of an alternative strategy to 
access the target arylnaphthyridinones. We previously reported a 
one-pot tandem Hurtleyretro-Claisen–cyclisation sequence to 
assemble isocoumarins from 2-bromo-3-nitrobenzoic acid and 
symmetrical and unsymmetrical -diketones.
42
 This was adapted 
to provide those arylnaphthyridinones which had been inaccess-
ible or accessible only with difficulty by the route shown in 
Scheme 1. In view of the difficulties experienced in separating 
mixtures of isocoumarins generated from unsymmetrical -diket-
ones,
42
 only symmetrical 1,3-diarylpropane-1,3-diones 37 were 
used in the present study. In contrast to the successful Hurtley 
couplings with 2-bromo-3-nitrobenzoic acid and with 3-bromo-
thiophene-4-carboxylic acid,
42,43
 only one example, 31, gave a 
usable yield of the corresponding pyranopyridinone 41a, with 
37a and CuI in boiling DMF. Liu et al. recently published
44
 a 
transition-metal-free variant of the Hurtley reaction, in which 2-
bromobenzoic acids are heated with -diketones in the presence 
of Cs2CO3 in acetonitrile; the SNAr reaction is followed by retro-
Claisen cleavage and cyclisation to form isocoumarins. Adapting 
this procedure to our target naphthyridinones, 2-bromopyridine-
3-carboxylic acid 38 was treated with excesses of the symmet-
rical -diketones 37b,c,e,f and Cs2CO3 in boiling acetonitrile to 
give excellent yields of the corresponding 7-arylpyrano[4,3-b]-
pyridin-5-ones 26b,c,e,f.The reaction failed for the electron-def-
icient -diketones 37d,k, even when the reaction temperature 
was increased by the use of boiling propionitrile as solvent. The 
C–Br bond is activated by the adjacent nitrogen in 38; it is also 
activated but to a lesser extent in 4-bromopyridine-3-carboxylic 
acid 39. Correspondingly, 39 reacted with the -diketones 37b,c,f 
to give the 3-arylpyrano[3,4-c]pyridin-1-ones 40b,c,f. Yields 
were lower, especially for 40f, corresponding to the need for a 
strongly nucleophilic electron-rich enolate. 3-Bromopyridine-4-
carboxylic acid 31, in which the C–Br bond is unactivated, failed 
to react with any -diketone, even under forcing conditions. The 
arylpyranopyridinones 26b,c,e,f, 40b,c,f were converted to the 
arylnaphthyridinones 9b,c,e,f, 11b,c,f with ammonia in 2-meth-
oxyethanol at elevated temperature and pressure. 
Scheme 3 shows the synthetic approaches to the arylpyridino-
pyrimidinones. The most widely used route to the carbocyclic 
analogues, the 2-arylquinazolin-4-ones, is acylation of appropr-
iately substituted anthranilamides at the amine nitrogen and base-
catalysed cyclisation.
4
 However, in transferring this method to 
the arylpyridinopyrimidinones, all attempts to acylate aminopyr-
idinecarboxamides with benzoyl chlorides failed. Liu et al. have 
reported an alternative access to quinazolinones through copper-
catalysed reaction of benzamidines with 2-bromobenzoic acids.
45
 
Adapting this method to our targets would need a series of 4-
substituted benzamidines 45 to provide diversity. 
Following the route of Anbazhagan et al.,
46
 attempts were 
made to convert the readily available 4-substituted benzonitriles 
42 into the 4-substituted N-methoxybenzamidines 43, prior to 
reduction of the N–O bond but the initial addition reaction failed 
for all but benzonitrile 42a and the electron-poor 4-trifluorometh-
ylbenzonitrile 42d. However, the benzonitriles did react well 
with hydroxylamine to give the N-hydroxyamidines 44 in excel-
lent yields for the electron-neutral and electron-deficient exam-
ples 42b,d-g,k,l but failed wholly or partly for the less electro-
philic compounds 42c (0% yield) and 42g (15%). Transfer hydro-
genolysis using ammonium formate and Pd/C (Pt/C for the halo 
analogues 44e,f) furnished the amidines 45a,b,d-g,l, with the 
nitro group of 44k being reduced simultaneously to afford 45g. 
Cu(I)-catalysed cyclocondensation of benzamidines 45a,b,d 
with 2-bromopyridine-3-carboxylic acid 38 afforded moderate 
yields of 2-arylpyrido[2,3-d]pyrimidin-4-ones 14a,b,d and a low 
yield of the chloro analogue 14e but the reaction failed for 
45f,g,l. Similar reactions of 45 with 4-bromopyridine-3-carb-
oxylic acid 37, where the C–Br is also activated, also gave good 
yields of 16a,b,d and a low yield of 16e and failed to provide 
16f,g,l. The isomeric 3-bromopyridine-4-carboxylic acid 31 was 
much less reactive, furnishing only 15a,b,d in poor yields. 
The amidines were also used in condensations with the cyclic 
-keto ester 46 to provide the intermediate 6-benzyl-protected 2-
aryl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-ones 47. Since 
the extended analogue 18j was also required, 4-phenylethynyl-
benzamidine 45j was prepared in two steps (Sonogashira coup-
ling of 42f with phenylethyne and reaction of the intermediate 
42j with NaOMe and NH4Cl). Condensation with 46 formed 47j 
in good yield. From 47a,b,d,g, the N-benzyl protection was 
removed by transfer hydrogenolysis under acidic conditions to 
give the target 2-aryl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-
4-ones 18a,b,d,g in good yields. Interestingly, the alkyne of 47j 
passed through this process unscathed to give 18j. 
2.3. Biochemical evaluation 
Compounds were each initially screened at three different 
concentrations for inhibition of the catalytic activity of human 
TNKS-2 (automodification), using an assay previously developed 
by us.
3,4
 The data are expressed in Table 1 as percentage inhibit-
ion of enzyme activity, relative to control (no inhibitor). IC50 
values were measured for some selected analogues showing more 
Scheme 2. Syntheses of pyranopyridinones 26, 40, 41 and naphthyridinones 9, 
11 via Hurtley couplings or transition metal-free SNAr reactions. Reagents & 
conditions: i, NaH, THF, Ar, 0ºC, then reflux; ii, 37, Cs2CO3,MeCN, reflux; iii, 
NH3, MeO(CH2)2OH, pressure, 100C; iv, 37a, CuI, K3PO4, DMF, Ar, 100°C. 
potency in the initial screen and for examples from each series 
(Table 2). These selected examples were also evaluated for inhib-
ition of TNKS-1 (co-substrate = histone-1) and counterscreened 
for isoform-selectivity using a PARP-1 inhibition assay, both as 
previously described.
3,4
 
Table 1. Initial screen of test compounds. Percentage inhibition of the catalytic activity of TNKS-2 by arylnaphthyridinones, 
aryltetrahydronaphthyridinones, arylpyridopyrimidinones and aryltetrahydropyridopyrimidinones. 
 
Cpd.  X,Y,Za R 100 mM 10 mM 1.0 mM 100 nM 10 nM 
9a X = N H   42  4 0 0 
9b X = N Me 97  8 100 39  3   
9c X = N OMe 93  19 51  22 0   
9d X = N CF3   14  24 14  10 1  10 
9e X = N Cl 100 96  26 35  25   
9f X = N Br  77  8 47  14 25  4  
9g X = N NH2  96  3 74  5 0  
9i X = N OH  96  5 58  6 3  13  
10a Z = N H   71  8 18  8 0 
10b Z = N Me  85  6 52  20 0  
10c Z = N OMe   78  3 31  11 0 
Scheme 3. Synthetic approaches to arylpyridopyrimidinones 14-16 and 2-aryl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-ones 18. Reagents & conditions: i, 
MeONH2.HCl, Na2CO3, MeOH, H2O (sonication for 42d); ii, NH2OH.HCl, NaHCO3, EtOH, H2O, reflux; iii, HCOONH4, Pd/C (Pt/C for 46e,f), AcOH, Ar, reflux; 
iv, 21a, (Ph3P)4Pd, CuI, Na ascorbate, Pr
i
2NH, THF, Ar, 40C; v, NH4Cl, NaOMe, MeOH, reflux; vi, 45, CuI, Cs2CO3, DMF, Ar, 80°C; vii, 45, NaOMe, MeOH, 
reflux; viii, HCOOH, Pd/C, MeOH. 
10g Z = N NH2   34  15 14  20 0 
11b Y = N Me  92  4 51  8 13  10  
11c Y = N OMe  97  1 50  13 9  15  
11e Y = N Cl  84  7 37  15 0  
12a X = N+–Me H   0 24  12 4  10 
12b X = N+–Me Me 100 100 83  12   
12c X = N+–Me OMe  12  5 9  5 0  
12d X = N+–Me CF3   24  4 0  
12e X = N+–Me Cl  9  6 8  10 17  9  
12f X = N+–Me Br  45  24 27  5 23  1  
12g X = N+–Me NH2  0 0 0  
13a X = N+–O- H   23  13 1  6 0 
13b X = N+–O- Me  100 94  2 12  15  
14a X = N H 0 0 0   
14b X = N Me 71  16 37  20 17  35   
14d X = N CF3  43  9 20  9 21  37  
14e X = N Cl  15  3 0 0  
15a Z = N H  80  14 29  6   
15b Z = N Me  93  7 18  18 0  
15d Z = N CF3  57  6 19  13 0  
16a Y = N H  15  9 20  4 0  
16b Y = N Me 86  1 62  11 43  19   
16d Y = N CF3  65  5 17  14 0  
16e Y = N Cl  81  9 9  6 9  4  
17a  H   99  4 78  3 43  9 
17c  OMe  100 82  10 93  15  
17d  CF3  95  3 86  5 82  19  
17e  Cl  91  14 89  11 24  12  
17f 
 Br  97  3 89  6 49  7  
18a  R2 = Ph, R6 = H  11  14 0 0  
18b  R2 = 4-MePh, R6 = H  35 ± 42 0 0  
18d  R2 = 4-F3CPh, R
6 = H  7  10 7  11 19  10  
18j  R2 = 4-PhC≡CPh, R6 = H  36  7 28  9 0  
18l 
 
R2 = pyridin-4-yl, R6 = H  0 0 0  
29a Z = N+–Me H  0 14  14 15  5  
36c Y = N+–Me OMe  0 0 0  
47a  R2 = Ph, R6 = Bn  0 0 0  
47b  R2 = 4-MePh, R6 = Bn  0 0 0  
47d  R2 = 4-F3CPh, R
6 = Bn  0 0 0  
47e  R2 = 4-ClPh, R6 = Bn   18  5 0  
47f  R2 = 4-BrPh, R6 = Bn  0 0 0  
47j  R2 = 4-PhC≡CPh, R6 = Bn  17 ± 15 7 ± 8 29 ± 20  
47l  R2 = pyridin-4-yl, R6 = Bn  39  9 0 0  
a Positions not indicated are CH. b Unoccupied cells = not determined. 
 
 
2.4. Structural studies 
Compounds 12b and 17a were crystallised with TNKS-2 to 
rationalise the design of inhibitors and to understand their mode 
of binding (PDB codes 4W5I and 4UX4, respectively). Although 
TNKS-2 was used in the crystallographic studies, the catalytic 
domains of TNKS-1 and TNKS-2 are highly homologous and the 
residues at the inhibitor-binding sites are completely conserved. 
TNKS-2-inhibitor complexes were crystallised containing two 
monomers in the asymmetric unit. As the two monomers are 
almost identical, the discussion will refer to monomer A in both 
of the structures. 
As expected, 12b and 17a bind to the nicotinamide-binding 
site of TNKS-2. The binding mode is typical of the PARP inhib-
itors, having the H-bonds to Gly
1032
 and Ser
1068
 and the canonical 
stacking interaction with Tyr
1071
. This binding is shown in Figure 
4 (B and C, respectively), with the corresponding structure of the 
isoquinolin-1-one 3 (R
4’
 = Me, R
5
 = OMe) for comparison (Fig-
ure 4A).
3
 The binding mode of the compounds is almost iden-
tical, despite the differences in the para-substitution on the 
phenyl ring and the saturation state and charge of the heterocyclic 
system. When compared with the TNKS-2-nicotinamide complex 
(PDB code 3U9H),
29
 both 12b and 17a induce a change in the 
side-chain of Phe
1035
, which moves ~1.1 Å towards the para-pos-
ition of the phenyl ring of the compounds. This may reflect the 
occupation of the hydrophobic cavity by the (substituted)phenyl 
of 12b and 17a, whereas this group is absent from the nicotin-
amide unit in NAD
+
. 
2.5. Structure-activity relationships 
Examining firstly the 7-aryl-1,6-naphthyridin-5-ones 9, it is 
clear that the replacement of carbon-5 of the 5-arylisoquinolin-1-
ones 3 with nitrogen has a markedly deleterious effect on binding 
and potency. For example, 9a, with a simple phenyl as the aryl 
group occupying the hydrophobic cavity, shows IC50 = 5 mM 
against TNKS-2 (Table 2), whereas the isoquinolinone analogue 
3 (R
4’
 = H, R
5
 = Me) has IC50 = 1.8 nM,
4
 indicating a loss of pot-
ency of some 1000-fold. The data from the initial three-concent-
ration screen (Table 1) confirm that there is similar loss of 
activity (relative to 3) for analogues with comparable para-subst-
itution on the aryl group. The nature of the para-substituent is 
relatively unimportant within this series, with polar groups (in 
9g,i) conveying similar activity to non-polar groups (in 9b,e,f). 
Interestingly, small electron-donating and electron-neutral groups 
are tolerated equally but an electron-withdrawing group (in 9d) 
and a slightly longer group (in 9c) reduce binding somewhat 
(Table 1). Moving the nitrogen to different positions in the naph-
thyridinone ring in 10 and 11 gives inhibitors of similar potency 
to 9 (Tables 1,2), i.e. 1000-fold loss of potency compared with 
the carbocyclic analogues 3. In both 10 and 11, the nature of the 
para-substituent on the phenyl is unimportant. Quaternisation of 
the ring-nitrogen in 12, placing the methyl at the same position as 
in the highly potent 8-methylquinazolinones 2 and the 5-methyl-
isoquinolinones 3 (R
5
 = Me), led to complete inactivity, except in 
the case of the 4-methylphenyl example 12b. Similarly, occup-
ying the small binding pocket with oxygen in the N-oxide 13a 
also diminished activity, although again the 4-methylphenyl anal-
ogue 13b retained some binding. Moving the quaternised 
+
N-Me 
cation to other positions in the ring, in 29a and 36c, abolished 
activity. This is unsurprising on steric grounds, as the methyl 
groups in these latter two compounds would clash severely with 
the protein surface in this part of the binding site; compounds 
with substituents in this region are very poor inhibitors of many 
of the PARP isoforms. 
Just as 9-11 are aza-analogues of the isoquinolinones 3, pyrid-
inopyrimidinones 14-16 are the aza-analogues of the quinazolin-
ones 2. There is also an approximately 1000-fold loss in potency 
in introducing the ring-nitrogen in these series (Table 1), comp-
ared with the parent quinazolinones 2.
3
 
Inhibition of the isoform TNKS-1 by 9a and 10a broadly foll-
owed the activity against TNKS-2 (Table 2). This is unsurprising, 
as their NAD
+
-binding domains have high homology. However, 
11b showed 17-fold selectivity for inhibition of TNKS-1 vs. 
TNKS-2 and is thus one of very few compounds to show this sel-
ectivity,
2
 although several show selectivity towards TNKS-2.
3
 
The dramatic loss in activity of the arylnaphthyridinones 9-11 
and the arylpyridopyrimidinones 14-16, compared with their 
carbocyclic equivalents 2 and 3, appears to be consequent to elec-
tron-deficiency. Whereas the potency is diminished 1000-fold for 
the uncharged analogues 9-11, 14-16, relative to 2, 3, it is red-
uced further for the cationic compounds 12 a,c-g. This observat-
ion is again consistent with electron-deficiency being deleterious 
to binding. A rationalisation may be an unfavourable interaction 
between the electron-poor rings and the positively charged side-
chain ammonium of Lys
1067
. As shown in crystal structures, this 
ammonium nitrogen is located only 5.5-6.0 Å from 1-N, 2-C and 
3-C in 12b (present work), whereas it is similarly located in the 
structure of the complex of 3 (R
4’
 = Me, R
5
 = OMe) to make an 
attractive interaction with the electron-rich carbocyclic ring of 
this latter ligand (Figure 4).
3
 By contrast, the partly-saturated 
tetrahydropyridine rings of 17a-f, active inhibitors of TNKS-2, 
are electron-rich and may also make attractive interactions with 
Lys
1067
 (Figure 4). 
Interestingly, the 7-aryl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-
ones 17 showed interesting inhibitory activity (Table 2). Comp-
ounds 11a,c-f all inhibited TNKS-2 with IC50 < 100 nM, with 
17c,d being more potent than XAV939 1.
3
 In this series, the 
para-substituent on the exocyclic phenyl ring had a marked effect 
on potency and isoform-selectivity The parent 17a had weaker 
and non-selective activity between the tankyrases. Analogues 17c 
and 17d (carrying OMe and CF3 groups, respectively) were high-
ly potent against both isoforms. Although the para-halo comp-
ounds 17e and 17f retained good potency against TNKS-2, they 
were much less active against TNKS-1, with 17f being a potent-
ially useful isoform-selective inhibitor of TNKS-2 (ca. 70-fold 
selectivity). The structural basis of the marked dependence of 
potency and selectivity on the nature of this para-substituent is 
unclear. What is clear is the close similarity of the conformation 
of 17, as bound into TNKS-2, and the bound conformation of 
XAV939 1. Figure 5 shows 1 and 17a as bound into TNKS-2, 
with the protein removed from the structure. This illustrates that 
both compounds adopt the same out-of-plane deformation of the 
(partly) saturated ring.  
Compounds 18 and 47 are aza analogues of 1, where the sul-
fur is replaced by a secondary amine (18) or a bulky tertiary 
amine (47). Both are strongly basic and would be expected to be 
protonated and cationic at physiological pH. As expected, the 
bulk of the benzyl group in this position in 47 abolishes binding 
and inhibitory activity (Table 1). Less expectedly, 18a,b,d,l are 
also devoid of activity against TNKS-2, with 18j (with the side-
chain extension) showing only slight inhibition (36%) at 10 mM. 
Compound 18d is the strict analogue of 1, so the >1000-fold loss 
of activity is remarkable. Given the close similarity in structure 
between 18 and 1, the loss of activity cannot be due to conform-
ational issues or to steric clash. The major difference between 1 
and 18 is that the neutral non-polar sulfur in the former is rep-
laced by a polar cationic entity in the latter. The buckling of the 
saturated ring of 1 (Figure 5) places the sulfur in a relatively hyd-
rophobic region, bent away from the ammonium of Lys
1067
.
25
 
Here the S is located 3.7 Å from the methyl of Ala
1062
 and imm-
ediately above the -bond of the backbone amide carbonyl of 
Phe
1061
, placing it 4.2 Å from the -CH2 of Lys
1067
. The proton-
ated cationic amine of 18 cannot make favourable interactions in 
this region. One may speculate that this unfavourable interaction 
is overcome to some extent by additional binding from the rigid 
linear phenylethynylphenyl unit in 18j to give the observed 
modest inhibition; this extension would project into the narrow 
tunnel at the distal side of the hydrophobic cavity, by analogy 
with the potent TNKS-2 inhibitor 3 (R
4’
 = -C≡CPh, R
5
 = Me).
3
 
The potent inhibitors of TNKS-1 and TNKS-2, 17a,c-f, were 
counterscreened for collateral inhibition of the superfamily 
member PARP-1 (Table 2). Only weak inhibition was observed 
in preliminary studies, indicating >1000-fold selectivity for the 
tankyrases for 17c,d, in line with similar selectivities seen for 
quinazolinones 2 and isoquinolinones 3.
3,4
 
2.6. Antiproliferative activity 
Selected analogues showing inhibition of tankyrases were ass-
essed for their antiproliferative activity against HT29 human 
colon carcinoma cells and against non-malignant FEK4 cells. 
The latter were isolated by Tyrrell from human foreskin and were 
a kind gift.
47
 They were used as a model for normal tissue. The 
MTS assay was used, as previously reported by us.
3,4
 Most of the 
compounds examined did not inhibit the proliferation of either 
cell-type (Table 3). However, 11b (a weak selective inhibitor of 
TNKS-1) had slight activity against HT29 cells. More striking 
was the selective toxicity of the 4’-halophenyl tetrahydronaphth-
yridinones 17e,f towards the HT29 colon cancer cells, leaving the 
“normal” cells unscathed. Isoform-selectivity in inhibition of the 
tankyrases appears to correlate with selective anticancer cytotox-
icity in this very preliminary study but there is, as yet, no evid-
ence of a causal relationship. 
3. Conclusions 
In this paper, we report the design of series of arylnaphthyrid-
inones and arylpyridopyrimidinones as aza analogues of 3-aryl-
isoquinolin-1-ones 3 and 2-arylquinazolin-4-ones 2 (known pot-
ent and selective inhibitors),
3,4
 respectively, to test the tolerance 
Table 2. IC50 values determined for inhibition of tankyrase-1, 
tankyrase-2 and PARP-1. 
 
Cpd. X,Y,Za R Tankyrase
-1 IC50 
(nM) 
Tankyrase
-2 IC50 
(nM) 
PARP-1 
IC50 (nM) 
1 [XAV939] 15 ± 4 15 ± 3 b 
9a X = N H 10.6  103 
± 6.9 × 103 
5  103 ± 
1.1 × 103 
 
10a Z = N H 2.2  103 ± 
0.2 × 103 
1.3  103 ± 
0.4 × 103 
 
11b Y = N Me 350 ± 140 6.2  103 ± 
0.4 × 103 
43 × 103 ± 
2 × 103 
17a  H 189 ± 1 97 ± 35 949 ± 217 
17c  OMe 1.7 ± 1.2 1.1 ± 0.4 3.4  103 ± 
1.0 × 103 
17d  CF3 7.5 ± 1.9 1.5 ± 0.4 4.8  10
3 ± 
1.6 × 103 
17e  Cl 134 ± 36 21 ± 1.4 2  103 
17f 
 Br 423 ± 256 6.1 ± 0.7 2  103 
a Positions not indicated are CH. b Unoccupied cells = not determined. 
 
Figure 5. Views of the structures of XAV939 1 and 17a as bound into 
tankyrase-2, showing similarity in conformation. 
1: XAV939 17a
Figure 4. Crystal structures of 12b (B) and 17a (C) bound into the 
nicotinamide-binding site and adjacent hydrophobic cavity of tankyrase-2. 
The corresponding structure of 5-methoxy-3-(4-methylphenyl)isoquinolin-1-
one 3 (R4’ = Me, R5 = OMe) bound into tankyrase-2 is shown for comparison 
(A).3 All three structures show the classical H-bonding motif of the lactam to 
Gly1032 and Ser1068 and the proximity of the benzene (A), pyridinium (B) and 
tetrahydropyridine rings of the inhibitors to the -N+H3 of Lys
1067. 
of the inhibitor-binding motif of the tankyrases to the additional 
ring-nitrogen. These compounds were assembled by acid-catal-
ysed cyclisation of the corresponding arylethynylpyridinenitriles 
to lactones and conversion to the naphthyridinones with amm-
onia. Methylation and oxidation took place at 1-N of 7-aryl-1,6-
naphthyridin-5-ones, to introduce a small group in the region of 
space occupied by the C-Me in the potent 3-aryl-5-methyliso-
quinolin-1-ones and 2-aryl-8-methylquinazolin-4-ones.
 3,4
 How-
ever, the electron-deficient pyridine ring in the naphthyridinones 
(replacing a benzene ring in the potent compounds) severely red-
uced binding and inhibitory potency, by up to three orders of 
magnitude. These results are rationalised by examining crystallo-
graphically the mode of binding of one analogue, 12b. This com-
pound makes the expected H-bonds with Gly
1032
 and Ser
106
, with 
the benzene ring in the centre of the adjacent hydrophobic cavity; 
however, binding may be reduced by the proximity of the pyrid-
ine / pyridinium to the positively charged side-chain of Lys
1067
. 
Examining more flexible analogues, the tetrahydropyridopyrim-
idines 18 are strict aza-analogues of the known inhibitor 
XAV939 (1)
9,25
 but replacement of lipophilic sulfur with (proton-
ated) nitrogen abolished activity, owing to unfavourable inter-
actions with the binding pocket, which is hydrophobic in this reg-
ion. By contrast the 7-aryl-1-methyltetrahydronaphthyridinones 
17 were highly potent for inhibition of the tankyrases. Interest-
ingly, a crystal structure of 17a bound into TNKS-2 revealed that 
it adopts the same buckle of the partly-saturated ring as does 1.
25
 
Compounds 17 were also shown to be selective for the tankyr-
ases, inhibiting PARP-1 only at mM concentrations. 
These studies have allowed more definition of the structure-
activity relationships for binding to and inhbiting the tankyrases, 
rationalised by structural understanding of the mode of binding. 
The identification of 17 as potent and selective inhibitors prov-
ides a new framework for design of improved agents and optim-
isation of pharmaceutical properties. 
4. Experimental 
4.1. Chemistry 
Chemical reagents were purchased from Sigma Aldrich, Goss 
Scientific, Alfa Aesar and Fisher Scientific and were used as 
supplied. 
1
H and 
13
C NMR spectra were recorded at 400.04 MHz 
or 500.13 MHz (
1
H) and 100.59 MHz or 125.76 MHz (
13
C), 
using (CD3)2SO containing SiMe4, unless otherwise noted. 
Signals in 
13
C NMR spectra were assigned using HSQC and 
HMBC and signals in 
15
N spectra with HMBC. Reactions were 
monitored by thin-layer chromatography on silica gel 60Å (part-
icle size 40-63 µm). MS data were obtained by electrospray ion-
isation using a microTOF MS (Bruker Daltonics, Germany) and 
were calibrated using HCO2Na. Melting points were measured 
using a heated stage microscope (Reichert-Jung). Experiments 
were at ambient temperature, unless otherwise noted. Solutions in 
organic solvents were dried with MgSO4. Experimental methods 
for the syntheses of 19h, 20c-e,g,h,l, 21c-e,g,l, 24, 31-34, 37b-f,l, 
42j, 43b,d, 44d,d-g,k,l and 45b,d-g,j,l can be found in the Supp-
lementary Information. 
4.1.1. 7-Phenyl-1,6-naphthyridin-5-one (9a) 
Compound 25a (300 mg, 1.5 mmol) was stirred under reflux 
in aq. H2SO4 (9 M, 20 mL) for 1 h. After cooling, aq. NaOH (5 
M) was added to pH 9. The mixture was extracted with EtOAc (5 
 25 mL). The combined extracts were dried. The evaporation 
residue was transferred into a pressure tube and dissolved in 
MeO(CH2)2OH (10 mL). NH3 was passed through the solution 
until it was saturated, the vessel was closed and the mixture was 
heated at 100C for 30 min. The mixture was cooled in ice and 
NH3 was passed through again, followed by closure and heating 
(30 min). The cycle was repeated twice. Evaporation and recryst-
allisation (MeO(CH2)2)OH) gave 9a (249 mg, 75%) as a white 
solid: mp 226-230C (lit.
30
 mp 228-229C); 
1
H NMR  6.98 (1 
H, s, 8-H), 7.54 (1 H, dd, J = 8.4, 4.9 Hz, 3-H), 7.57-7.60 (3 H, 
m, Ph 3,4,5-H3), 7.89 (2 H, d, J = 7.9 Hz, Ph 2,6-H2), 8.57 (1 H, 
dd, J = 8.0, 1.3 Hz, 4-H), 8.98 (1 H, dd, J = 4.5, 1.8 Hz, 2-H), 
11.74 (br, NH); 
13
C NMR  104.56 (8-C), 120.40 (3-C), 121.62 
(4a-C), 126.99 (Ph 3,5-C2), 128.82 (Ph 2,6-C2), 129.82 (Ph 4-C), 
133.36 (Ph 1-C), 135.00 (4-C), 143.97 (7-C), 154.16 (2-C), 
154.97 (8a-C), 162.93 (5-C); 
15
N NMR ((CD3)2SO)  124.89 (6-
N), 278.87 (1-N), MS m/z 245.0676 (M + Na)
+
 (C14H10N2NaO 
requires 245.0691). 
4.1.2. 7-(4-Methylphenyl)-1,6-naphthyridin-5-one (9b) 
Compound 25b was treated with H2SO4, then NH3, as for the 
synthesis of 9a, to give 9b (48%) as an off-white solid: mp 255-
258C; 
1
H NMR  2.43 (3 H, s, Me), 6.95 (1 H, s, 8-H), 7.38 (2 
H, d, J = 8.0 Hz, Ph 3,5-H2), 7.54 (1 H, dd, J = 8.0, 4.5 Hz, 3-H), 
7.79 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.55 (1 H, ddd, J = 8.0, 1.6, 
0.7 Hz, 4-H), 8.97 (1 H, dd, J = 4.5, 1.8 Hz, 2-H), 11.74 (1 H, br, 
NH); 
13
C NMR  20.81 (Me), 103.99 (8-C), 120.27 (4a-C), 
121.43 (3-C), 126.82 (Ph 2,6-C2), 129.38 (Ph 3,5-C2), 130.54 (Ph 
1-C), 134.97 (4-C), 139.60 (Ph 4-C), 144.01 (7-C), 154.27 (8a-
C), 154.93 (2-C), 162.94 (5-C); MS m/z 259.0826 (M + Na)
+
 
(C15H12N2NaO requires 259.0847). 
4.1.3. 7-(4-Methoxyphenyl)-1,6-naphthyridin-5-one (9c) 
Compound 25c was treated with H2SO4, then NH3, as for the 
synthesis of 9a, to give 9c (70%) as an off-white solid: mp 276-
280C; 
1
H NMR  3.89 (3 H, s, Me), 6.92 (1 H, s, 8-H), 7.12 (2 
H, d, J = 8.9 Hz, Ph 3,5-H2), 7.50 (1 H, dd, J = 8.0, 4.6 Hz, 3-H), 
7.86 (2 H, d, J = 8.9 Hz, Ph 2,6-H2), 8.54 (1 H, dd, J = 8.0, 1.8 
Hz, 4-H), 8.95 (1 H, dd, J = 4.5, 1.8 Hz, 2-H), 11.65 (1 H, br, 
NH); 
13
C NMR  55.36 (Me), 114.24 (Ph 3,5-C2), 120.01 (8-C), 
122.42 (4a-C), 123.65 (Ph 1-C), 125.60 (3-C), 128.39 (Ph 2,6-
C2), 134.94 (7-C), 136.92 (4-C), 143.77 (2-C), 154.90 (8a-C), 
156.99 (5-C), 158.82 (Ph 4-C); MS m/z 275.0767 (M + Na)
+
 
(C15H12N2NaO2 requires 275.0796), 253.0978 (M + H)
+
 
(C15H13N2O2 requires 253.0977). 
Table 3. Antiproliferative activities against HT29 human 
colon carcinoma cells and FEK4 human fibroblasts. 
 
Cpd. 
No. 
X,Y,Za R HT29 
IC50 (mM) 
FEK4 
IC50 (mM) 
9a X = N H >500b >500b 
10a Z = N H >500b >500b 
11b Y = N Me 157 ± 88 >500b 
17a  H >500b >500b 
17c  OMe >200b >200b 
17d  CF3 >200
b >200b 
17e  Cl 26 ± 5 >500b 
17f 
 Br 26 ± 5 >500b 
a Positions not indicated are CH. b Limited by solubility. 
 
4.1.4. 7-(4-Trifluoromethylphenyl)-1,6-naphthyridin-5-one 
(9d) 
Compound 25d was treated with H2SO4, then NH3, as for the 
synthesis of 9a, to give 9d (55%) as a white solid: mp >325C; 
1
H NMR  7.03 (1 H, s, 8-H), 7.53 (1 H, dd, J = 8.0, 4.6 Hz, 3-
H), 7.92 (2 H, d, J = 8.4 Hz, Ph 3,5-H2), 8.10 (2 H, d, J = 8.2 Hz, 
Ph 2,6-H2), 8.53 (1 H, dd, J = 8.0, 1.7 Hz, 4-H), 9.00 (1 H, dd, J 
= 4.5, 1.8 Hz, 2-H), 11.25 (1 H, br, NH); 
13
C NMR 105.92 (8-C), 
120.90 (4a-C), 122.13 (3-C), 124.1 (q, J = 264 Hz, CF3), 125.62 
(q, J = 3.6 Hz, Ph 3,5-C2), 128.03 (Ph 2,6-C2), 129.78 (q, J = 32 
Hz, Ph 4-C), 135.05 (4-C), 137.31 (Ph 1-C), 142.51 (7-C), 
153.90 (2-C), 155.09 (8a-C), 162.86 (5-C); 
15
N NMR  123.4 (6-
N), 279.7 (1-N); 
19
F NMR  -61.20 (s, CF3); MS m/z 291.0727 
(M + H)
+
 (C15H10N2O requires 291.0745). 
4.1.5. 7-(4-Chlorophenyl)-1,6-naphthyridin-5-one (9e) 
Compound 25e was treated with H2SO4, then NH3, as for the 
synthesis of 9a, to give 9d (33%) as an off-white solid: mp 296-
298C; IR max 3163, 1669, 1627, 1588, 720 cm
-1
; 
1
H NMR  
6.95 (1 H, s, 8-H), 7.50 (1 H, dd, J = 8.0, 4.5 Hz, 3-H), 7.58 (2 H, 
d, J = 9.0 Hz, Ph 3,5-H2), 7.91 (2 H, d, J = 8.5 Hz, Ph 2,6-H2), 
8.51 (1 H, d, J = 8.0 Hz, 4-H), 8.98 (1 H, d, J = 4.5 Hz, 2-H), 
11.74 (1 H, br, NH); 
13
C  104.95 (8-C), 120.58 (4a-C), 121.83 
(3-C), 128.82 (Ph 3,5-C2), 128.93 (Ph 2,6-C2), 134.60 (4-C), 
135.03 (Ph 1-C), 155.05 (C=O), 162.90 (8a-C); 
15
N NMR 
(HMBC)  124.20 (s, 6-N); MS m/z 279.0278 (M + Na)
+
 
(C14H9
35
ClN2NaO requires 279.0296), 259.0420 (M + H)
+
 
(C14H10
37
ClN2O requires 259.0450), 257.0482 (M + H)
+
 
(C14H10
35
ClN2O requires 257.0476). 
4.1.6. 7-(4-Bromophenyl)-1,6-naphthyridin-5-one (9f) 
NH3 was bubbled through 26f (140 mg, 0.47 mmol) in 
MeO(CH2)2OH (10 mL) for 10 min in a pressure vessel. The 
vessel was closed and the mixture was heated at 120ºC for 30 
min. The reaction mixture was cooled in ice and NH3 was bubb-
led again, followed by closure and heating (30 min). The cycle 
was repeated twice. Evaporation and recrystallisation (EtOH) 
gave 9f (100 mg, 75%) as a buff powder: mp 304-305ºC; 
1
H 
NMR  7.05 (1 H, s, 8-H), 7.50 (1 H, dd, J = 7,7, 4.0 Hz, 3-H), 
7.39 (2 H, d, J = 8 Hz, Ph 3,5-H2), 7.84 (2 H, d, J = 8 Hz, Ph 2,6-
H2), 8.30 (1 H, d, J = 7.7 Hz, 4-H), 8.69 (1 H, d, J = 4.8 Hz, 2-
H), 9.15 (1 H, br, NH); 
13
C NMR  105.80 (8-C), 122.51 (4a-C), 
122.97 (Ph 4-C), 123.61 (3-C), 127.41 (Ph 1-C), 130.22 (Ph 2,6-
C2), 130.75 (Ph 3,5-C2), 131.91 (7-C), 134.61 (4-C), 156.71 (8a-
C), 168.09 (5-C); MS m/z 627 / 625 / 623 (2 M + Na)
+
, 324.9771 
(M + Na)
+
 (C14H9
81
BrN2NaO requires 324.9774), 322.9790 (M + 
Na)
+
 (C14H9
79
BrN2NaO requires 322.9805), 302.9964 (M + H)
+
 
(C14H10
81
BrN2O requires 302.9951), 301.0024 (M + H)
+
 
(C14H10
79
BrN2O requires 300.9971). 
4.1.7. 7-(4-Aminophenyl)-1,6-naphthyridin-5-one (9g) 
Compound 26g was treated with H2SO4, then NH3, as for the 
synthesis of 9a, to give 9g (66%) as a yellow powder: mp 
>300ºC; 
1
H NMR  5.65 (2 H, br, NH2), 6.80 (1 H, s, 8-H), 7.43 
(1 H, dd, J = 8.0, 4.5 Hz, 3-H), 7.60 (2 H, d, J = 8.6 Hz, Ph 3,5-
H2), 7.71 (2 H, d, J = 8.7 Hz, Ph 2,6-H2), 8.49 (1 H, dd, J = 8.0, 
1.8 Hz, 4-H), 8.90 (1 H, dd, J = 4.8, 1.8 Hz, 2-H), 11.50 (1 H, br, 
NH); 
13
C NMR  99.08 (8-C), 113.59 (Ph 3,5-C2), 117.55 (3-C), 
122.16 (4a-C), 124.87 (Ph 1-C), 127.78 (4-C), 130.51 (Ph 2,6-
C2), 136.95 (7-C), 150.62 (2-C), 153.57 (Ph 4-C), 156.59 (8a-C), 
161.65 (5-C). 
4.1.8. 7-(4-Hydroxyphenyl)-1,6-naphthyridin-5-one (9i) 
Compound 25h was treated with H2SO4, then NH3, as for the 
synthesis of 9a, to give 9i (10%) as a pale buff solid: mp 258-
260C; IR max 3423, 1660, 1617, 1589 cm
-1
;
 1
H NMR  6.87 (1 
H, s, 8-H), 6.93 (2H, d, J = 8.6 Hz, Ph 2,6-H2), 7.37 (1 H, d, J = 
7.4 Hz, 3-H), 7.73 (2 H, d, J = 8.6 Hz, Ph 3,5-H2), 8.52 (1 H, d, J 
= 2.5 Hz, 4-H), 8.94 (1 H, d, J = 2.5 Hz, 2-H), 9.99 (1 H, br, 
OH), 11.67 (1 H, br, NH); 
13
C NMR  115.57 (8-C), 119.0 (3-C), 
121.0 (Ph 1-C), 126.0 (4a-C), 128.11 (Ph 2,6-C2), 128.42 (Ph 3,5-
C2), 135.0 (4-C), 147.0 (2-C), 153.0 (Ph 4-C), 154.89 (8a-C), 
163.0 (5-C); MS m/z 239.0816 (M + H)
+
 (C14H11N2O2 requires 
239.0816); MS m/z 237.0632 (M - H)
-
 (C14H9N2O2 requires 
237.0659). 
4.1.9. 3-Phenyl-2,6-naphthyridin-1-one (10a) 
Compound 35a (100 mg, 0.49 mmol) was stirred at 120C in 
polyphosphoric acid (10 mL) for 1 h. After cooling, aq. NaOH (5 
M) was added to pH 8. The mixture was extracted (EtOAc, 3×). 
The combined extracts were dried. The evaporation residue was 
transferred into a pressure tube and dissolved in MeO(CH2)2OH 
(5 mL). NH3 was bubbled through the solution, the vessel was 
closed and the mixture was heated at 130C for 30 min. The reac-
tion mixture was cooled in ice and NH3 was bubbled again, foll-
owed by closure and heating (30 min). The cycle was repeated 
thrice. Evaporation and trituration (EtOH) gave an inseparable 
mixture of 10a and 32 (85 mg) as a gum. 
1
H NMR showed that 
the mixture comprised 10a (56% yield) and 32 (22% yield). 10a: 
1
H NMR δ 7.11 (1 H, s, 4-H), 7.39 (1 H, m, Ph 4-H), 7.42 (2 H, 
m, Ph 3,5-H2), 7.67 (2 H, d, J = 7.0 Hz, Ph 2,6-H2), 8.64 (1 H, s, 
8-H), 8.70 (1 H, s, 7-H), 8.99 (1 H, s, 5-H), 11.68 (1 H, br, NH); 
13
C NMR δ 101.50 (4-C), 121.20 (8-C), 125.50 (m, Ph 3,4,5-C3), 
128.50 (Ph 2,6-C2), 131.00 (Ph 1-C), 132.90 (8a-C), 146.50 (7-
C), 151.50 (5-C); MS m/z 223.0875 (M + H)
+
 (C14H11N2O 
requires 223.0866). 32: 
1
H NMR δ 7.10 (1 H, s, 4-H), 7.86 (2 H, 
d, J = 8.2 Hz, Ph 2,6-H2), 7.98-8.00 (3 H, m, Ph 3,4,5-H3), 8.08 
(1 H, d, J = 5.2 Hz, 8-H), 8.67 (1 H, d, J = 5.3 Hz, 7-H), 9.17 (1 
H, s, 5-H); 
13
C NMR  98.52 (4-C), 118.0 (8-C), 125.42 (Ph 2,6-
C2), 127.00 (8a-C), 129.01 (Ph 3,5-C2), 130.64 (Ph 4-C), 131.20 
(Ph 1-C), 132.00 (3-C), 148.44 (7-C), 149.00 (5-C), 151.00 (1-
C); MS m/z 245 (M + Na), 223.0875 (M + H)
+
 (C14H11N2O 
requires 223.0866). 
4.1.10. 3-(4-Methylphenyl)-2,6-naphthyridin-1-one (10b) 
Compound 35b was treated with polyphosphoric acid, then 
with NH3, as for the synthesis of 10a, except that the product was 
recrystallised (EtOH) to give 10b (6%) as an off-white solid: mp 
188-189C; 
1
H NMR  7.07 (1 H, s, 4-H), 7.38 (2 H, d, J = 7.9 
Hz, Ph 3,5-H2), 7.76 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.04 (1 H, d, 
J = 5.3 Hz, 8-H), 8.66 (1 H, d, J = 5.3 Hz, 7-H), 9.15 (1 H, d, J = 
0.8 Hz, 5-H), 11.90 (1 H, br, NH); 
13
C NMR  20.70 (Me), 
100.10 (4-C), 119.80 (8-C), 127.10 (Ph 2,6-C2), 129.53 (Ph 3,5-
C2), 146.20 (7-C), 148.90 (5-C); MS m/z 495.1796 (2 M + Na)
+
 
(C30H24N4NaO2 requires 495.1797), 259.0834 (M + Na)
+
 
(C15H12N2NaO requires 259.0847), 237.1022 (M + H)
+
 
(C15H13N2O requires 237.1028). 
4.1.11. 3-(4-Methoxyphenyl)-2,6-naphthyridin-1-one (10c) 
Compound 35c was treated with polyphosphoric acid, then 
NH3, as for the synthesis of 10b, to give 10c (37%) as an off-
white solid: mp 244-245C; 
1
H NMR  3.90 (3 H, s, Me), 7.11 (1 
H, s, 4-H), 7.12 (2 H, d, J = 8.4 Hz, Ph 3,5-H2), 7.63 (2 H, d, J = 
8.9 Hz, Ph 2,6-H2), 7.80 (1 H, d, J = 5.1 Hz, 8-H), 8.83 (1 H, d, J 
= 5.1 Hz, 7-H), 9.04 (1 H, s, 5-H); 
13
C NMR  55.54 (Me), 
113.87 (Ph 3,5-C2), 114.74 (4-C), 121.10 (4a-C), 124.89 (8-C), 
130.32 (Ph 2,6-C2), 131.82 (Ph 1-C), 134.20 (8a-C), 135.10 (3-
C), 149.01 (7-C), 152.10 (5-C), 160.42 (1-C), 160.99 (Ph 4-C); 
MS m/z 527.1679 (2 M + Na)
+
 (C30H24N4NaO4 requires 
527.1695), 275.0772 (M + Na)
+
 (C15H12N2NaO2 requires 
275.0796), 253.0960 (M + H)
+
 (C15H13N2O2 requires 253.0977). 
4.1.12. 3-(4-Chlorophenyl)-2,6-naphthyridin-1-one (10e) 
Compound 35e was treated with polyphosphoric acid, then 
NH3, as for the synthesis of 10b, to give 10e (27%) as an off-
white solid: mp 257-259C; 
1
H NMR  7.12 (1 H, s, 4-H), 7.64 
(2 H, d, J = 8.7 Hz, Ph 3,5-H2),7.88 (2 H, d, J = 8.6 Hz, Ph 2,6-
H2), 8.05 (1 H, d, J = 5.3 Hz, 8-H), 8.69 (1 H, d, J = 5.3 Hz, 7-
H), 9.17 (1 H, s, 5-H), 11.75 (1 H, br, NH); 
13
C NMR  101.92 
(4-C), 119.10 (8-C), 128.73 (Ph 2,6-C2), 128.82 (Ph 3,5-C2), 
130.01 (4a-C), 132.05 (Ph 1-C), 134.10 (Ph 4-C),137.10 (8a-C), 
142.00 (3-C), 146.53 (7-C), 150.20 (5-C), 156.31 (1-C); MS m/z 
279 (M + Na)
+
, 257.0475 (M + H)
+
 (C14H10
35
ClN2O requires 
257.0482). 
4.1.13. 3-Phenyl-2,7-naphthyridin-1-one (11a) 
Compound 28a (300 mg, 1.5 mmol) was stirred under reflux 
in aq. H2SO4 (9 M, 20 mL) for 1 h. After cooling, aq. NaOH (5 
M) was added to pH 9. The mixture was extracted with EtOAc (5 
 25 mL). The evaporation residue was transferred into a press-
ure tube and dissolved in MeO(CH2)2OH (10 mL). NH3 was 
passed through the solution, the vessel was closed and the mix-
ture was heated at 100C for 30 min. The reaction mixture was 
cooled in ice and NH3 was passed through again, followed by 
closure and heating (30 min). The cycle was repeated twice. 
Evaporation and recrystallisation (MeO(CH2)2OH) gave 11a (131 
mg, 40%) as an off-white solid: mp 236-237C (lit.
34
 237-
238°C); IR max 3447, 1669, 1631, 1595, 1461 cm
-1
; 
1
H NMR  
6.97 (1 H, s, 4-H), 7.58 (3 H, m, Ph 3,4,5-H3), 7.66 (1 H, d, J = 
5.4 Hz, 5-H), 7.86 (2 H, dd, J = 7.6 Hz, Ph 2,6-H2), 8.76 (1 H, d, 
J = 5.4 Hz, 6-H), 9.38 (1 H, s, 8-H), 11.91 (1 H, br, NH); 
13
C 
NMR  101.41 (4-C), 119.66 (5-C), 127.12 (Ph 2,6-C2), 128.87 
(Ph 3,5-C2), 130.14 (Ph 4-C), 133.26 (Ph 1-C), 143.11 (4a-C), 
145.27 (8a-C), 149.84 (8-C), 150.98 (6-C), 162.37 (1-C); MS m/z 
223.0866 (M + H)
+
 (C14H11N2O requires 223.0935). 
4.1.14. 3-(4-Methylphenyl)-2,7-naphthyridin-1-one (11b) 
NH3 was bubbled through 40b (35 mg, 0.15 mmol) in MeO-
(CH2)2OH (10 mL) for 10 min in a pressure vessel. The vessel 
was closed and the mixture was heated at 120ºC for 30 min. The 
reaction mixture was cooled in ice and NH3 was bubbled again, 
followed by closure and heating (30 min). The cycle was rep-
eated twice. Evaporation and recrystallisation (EtOH) gave 11b 
(12 mg, 31%) as an off-white powder: mp > 300ºC (decomp.); 
1
H 
NMR  2.43 (3 H, s, Me), 6.94 (1 H, s, 4-H), 7.38 (2 H, d, J = 8.1 
Hz, Ph 3,5-H2), 7.63 (1 H, d, J = 5.6 Hz, 5-H), 7.77 (2 H, d, J = 
8.2 Hz, Ph 2,6-H2), 8.73 (1 H, d, J = 5.5 Hz, 6-H), 9.36 (1 H, s, 8-
H), 11.70 (1 H, br, NH); 
13
C NMR  21.16 (Me), 100.79 (4-C), 
119.55 (8a-C), 127.40 (Ph 2,6-C2,), 128.67 (5-C), 129.38 (Ph 3,5-
C2), 129.40 (Ph 1-C), 144.10 (Ph 4-C), 145.23 (4a-C), 146.00 (3-
C), 150.88 (8-C), 153.00 (6-C), 162.36 (1-C); MS m/z 495 (2 M 
+ Na)
+
, 259.0841 (M + Na)
+
 (C15H12N2NaO requires 259.0842). 
4.1.15. 3-(4-Methoxyphenyl)-2,7-naphthyridin-1-one (11c) 
Compound 28c was treated with H2SO4, then NH3, as for the 
synthesis of 11a, to give 11c (32%) as a pale orange solid: mp 
>300C (decomp.); 
1
H NMR  3.89 (3 H, s, Me), 6.90 (1 H, s, 4-
H), 7.13 (2 H, d, J = 8.5 Hz, Ph 3,5-H2), 7.62 (1 H, d, J = 8.9 Hz, 
5-H), 7.84 (2 H, d, J = 9.0 Hz, Ph 2,6-H2), 8.72 (1 H, d, J = 5.4, 
1.3 Hz, 6-H), 9.35 (1 H, s, 8-H), 11.82 (1 H, br, NH); 
13
C NMR  
55.41 (Me), 100.15 (4-C), 114.27 (Ph 3,5-C2), 119.34 (4a-C), 
119.44 (5-C), 125.39 (Ph 1-C), 128.54 (Ph 2,6-C2), 143.26 (8a-
C), 145.02 (3-C), 149.80 (8-C), 150.84 (6-C), 160.78 (Ph 4-C), 
162.40 (1-C); MS m/z 253.0985 (M + Na)
+
 (C15H13N2O2 requires 
253.0972). 
4.1.16. 3-(4-Aminophenyl)-2,7-naphthyridin-1-one (11g) 
Compound 28g (40 mg, 0.18 mmol) was stirred under reflux 
in aq. H2SO4 (9 M, 20 mL) for 1 h. After cooling, aq. NaOH (5 
M) was added to pH 9. The mixture was extracted (EtOAc, 5  
25 mL). Aq. HCl (9 M) was added to the aqueous layer to pH 1. 
The latter was washed thrice with EtOAc. The solution was bas-
ified with aq. NaOH (5 M) to pH 9 and extracted with EtOAc (5 
). The extracts were dried. Evaporation and recrystallisation 
(EtOAc) gave 11g (15 mg, 36%) as a white solid: mp 235-236C; 
IR max 3172, 1669, 1617, 1594 cm
-1
; 
1
H NMR  5.71 (2 H, br, 
NH2), 6.69 (2 H, dd, J = 8.8 Hz, Ph 3,5-H2), 6.77 (1 H, s, 4-H), 
7.54 (1 H, d, J = 5.7 Hz, 5-H), 7.59 (2 H, d, J = 8.8 Hz, Ph 2,6-
H2), 8.65 (1 H, d, J = 5.4 Hz, 6-H), 9.28 (1 H, s, 8-H), 11.74 (1 
H, br, NH); 
13
C NMR  97.99 (4-C), 112.43 (Ph 1-C), 113.48 
(3,5-C2), 199.10 (5-C), 127.96 (2,6-C2), 130.41 (3-C), 143.56 
(4a-C), 145.99 (8a-C), 150.55 (8-C), 150.91 (6-C), 152.0 (Ph 4-
C), 162.46 (1-C); MS m/z 238.0950 (M + H)
+
 (C14H12N3O 
requires 238.0975). 
4.1.17. 1-Methyl-5-oxo-7-phenyl-1,6-naphthyridinium iodide 
(12a) 
MeI (410 mg, 2.9 mmol) was stirred with 9a (120 mg, 0.54 
mmol) in dry DMF (5 mL) for 36 h. The mixture was poured into 
Me2CO (3 mL). The solid was collected, washed (Me2CO) and 
dried to give 12a (142 mg, 72%) as a yellow solid: mp 280-
284C, 
1
H NMR  4.40 (3 H, s, Me), 7.18 (1 H, s, 8-H), 7.63 (3 
H, m, Ph 3,4,5-H3), 7.88 (1 H, dd, J = 8.0, 6.0 Hz, 3-H), 7.98 (2 
H, d, J = 7.5 Hz, Ph 2,6-H2), 9.09 (1 H, d, J = 7.5 Hz, 4-H), 9.20 
(1 H, d, J = 5.5 Hz, 2-H), 12.87 (1 H, s, 6-H); 
13
C NMR  44.97 
(Me), 93.61 (8-C), 121.24 (3-C), 123.03 (4a-C), 128.05 (Ph 2,6-
C2), 128.98 (Ph 3,5-C2), 131.55 (Ph 4-C), 132 (Ph 1-C), 144.13 
(4-C), 147.98 (8a-C), 150.91, 153 (7-C), 161 (5-C); MS m/z 
237.1012 (M)
+
 (C15H13N2O requires 237.1022). 
4.1.18. 1-Methyl-7-(4-methylphenyl)-5-oxo-1,6-naphthyridin-
1-ium iodide (12b) 
Compound 9b was treated with MeI, as for the synthesis of 
12a, to give 12b (64%) as a yellow solid: mp 273-276C; IR max 
3431, 3250, 1665, 1606, 1507 cm
-1
; 
1
H NMR  2.41 (3 H, s, 
PhMe), 4.38 (3 H, s, NMe), 7.13 (1 H, s, 8-H), 7.40 (2 H, d, J = 
8.0 Hz, Ph 3,5-H2), 7.82 (1 H, m, 3-H), 7.92 (2 H, d, J = 8.0 Hz, 
Ph 2,6-H2), 9.04 (1 H, d, J = 8.0 Hz, 4-H), 9.16 (1 H, br, 2-H); 
13
C NMR  20.99 (PhMe), 44.80 (NMe), 92.55 (8-C), 120.59 (3-
C), 122.78 (4a-C), 127.91 (Ph 2,6-C2), 129.43 (Ph 1-C), 129.52 
(Ph 3,5-C2), 141.69 (Ph 4-C), 143.98 (4-C), 148.05 (8a-C), 
150.55 (2-C), 153.5 (br, 7-C); 
15
N NMR  155.00 (1-N); MS m/z 
251.1175 (M)
+
 (C16H15N2O requires 251.1179). 
4.1.19. 7-(4-Methoxyphenyl)-1-methyl-5-oxo-1,6-naphthyrid-
in-1-ium iodide (12c) 
MeI (144 mg, 1.0 mmol) was stirred with 9c (76 mg, 0.3 
mmol) in dry DMF (5 mL) for 3 d. The mixture was poured into 
EtOAc (25 mL) and petroleum ether (25 mL). The solid was coll-
ected, washed (petroleum ether) and dried to give 12c (5.0 mg, 
4%) as a yellow solid: mp >300°C (decomp.); 
1
H NMR  3.94 (3 
H, s, OMe), 4.46 (3 H, s, NMe), 7.19 (1 H, s, 8-H), 7.22 (2 H, d, 
J = 8.9 Hz, Ph 3,5-H2), 7.93 (1 H, dd, J = 8.0, 6.2 Hz, 3-H), 8.04 
(2 H, d, J = 8.9 Hz, Ph 2,6-H2), 9.13 (1 H, d, J = 7.5 Hz, 4-H), 
9.25 (1 H, d, J = 6.3 Hz, 2-H), 12.77 (1 H, br, NH); 
13
C NMR  
44.0 (NMe), 57.0 (OMe), 127.0 (Ph 2,6-C2), 132.0 (Ph 3,5-C2), 
148.0 (4-C); MS m/z 267.1136 (M)
+
 (C16H15N2O2 requires 
267.1134). 
4.1.20. 1-Methyl-5-oxo-7-(4-trifluoromethylphenyl)-1,6-naph-
thyridin-1-ium iodide (12d) 
Compound 9d (30 mg, 0.21 mmol) was stirred with MeI (90 
mg, 0.63 mmol) in dry DMF (5 mL) for 72 h. The mixture was 
poured into EtOAc (3 mL). The solid was collected, washed 
(EtOAc) and dried to give 12d (40 mg, 90%) as a yellow solid. 
mp 298-299C; 
1
H NMR  4.45 (3 H, s, Me), 7.31 (1 H, s, 8-H), 
7.59 (1 H, m, 3-H), 7.99 (2 H, d, J = 8.8 Hz, Ph 2,6-H2), 8.17 (2 
H, d, J = 6.4 Hz, Ph 3,5-H2), 9.15 (1 H, d, J = 6.4 Hz, 4-H), 9.30 
(1 H, d, J = 4.4 Hz, 2-H), 13.00 (1 H, br, NH); 
13
C NMR  45.34 
(Me), 95.52 (8-C), 122.44 (3-C), 123.64 (4a-C), 124.94 (q, J = 
271.0 Hz, CF3), 125.81 (q, J = 3.6 Hz, Ph 3,5-C2), 129.21 (Ph 
2,6-C2), 131.16 (q, J = 34.0 Hz, Ph 4-C), 136.15 (7-C), 144.30 
(3-C), 147.81 (8a-C), 149.89 (Ph 1-C), 151.41 (2-C), 160.46 (1-
C); 
19
F NMR ((CD3)2SO)  -61.35 (s, CF3); MS m/z 305.0895 
(M)
+
 (C16H12F3N2O requires 305.0896). 
4.1.21. 7-(4-Chlorophenyl)-1-methyl-5-oxo-1,6-naphthyridin-
1-ium iodide (12e) 
MeI (226 mg, 1.6 mmol) was stirred with 9e (78 mg, 0.3 
mmol) in dry DMF (5 mL) for 4 d. The evaporation residue was 
washed (EtOAc, petroleum ether) and dried to give 12e (20 mg, 
16%) as a yellow solid: mp >300C (decomp.); 
1
H NMR  4.42 
(3 H, s, Me), 7.26 (1 H, s, 8-H), 7.84 (1 H, dd, J = 6.5, 5.8 Hz, 3-
H), 7.99 (2 H, d, J = 8.3 Hz, Ph 2,6-H2), 8.31 (2 H, d, J = 8.2 Hz, 
Ph 3,5-H2), 9.07 (1 H, d, J = 6.5 Hz, 4-H), 9.18 (1 H, d, J = 5.8 
Hz, 2-H), 12.53 (1 H, br, NH); 
13
C NMR  48.56 (Me), 90.0 (8-
C), 118.0 (3-C), 127.0 (Ph 2,6-C2), 130.0 (Ph 3,5-C2), 151.0 (2-
C); MS m/z 273.0626 (M)
+
 (C15H12
37
ClN2O requires 273.0608); 
271.0634 (M)
+
 (C15H12
35
ClN2O requires 271.0638). 
4.1.22. 7-(4-Bromophenyl)-1-methyl-5-oxo-1,6-naphthyridin-
1-ium iodide (12f) 
Compound 9f was treated with MeI, as for the synthesis of 
12a, to give 12f (52%) as a yellow solid: mp 292-294C, 
1
H 
NMR  4.48 (3 H, s, Me), 7.29 (1 H, s, 8-H), 7.89 (2 H, d, J = 8.7 
Hz, Ph 2,6-H2), 7.97 (1 H, m, 3-H), 7.98 (2 H, d, J = 8.7 Hz, Ph 
3,5-H2), 9.18 (1 H, d, J = 7.9 Hz, 4-H), 9.30 (1 H, d, J = 5.8 Hz, 
2-H), 12.94 (1 H, s, NH); 
13
C NMR  45.98 (Me), 95.00 (8-C), 
122.40 (3-C), 123.00 (4a-C), 126.00 (Ph 4-C), 130.12 (Ph 2,6-
C2), 130.50 (Ph 1-C), 131.98 (Ph 3,5-C2), 132.55 (3-C), 144.50 
(4-C), 148.50 (8a-C), 152.50 (2-C), 155.5 (1-C); MS m/z 
317.0108 (M)
+
 (C15H12
81
BrN2NaO requires 317.0221), 315.0128 
(M)
+
 (C15H12
79
BrN2NaO requires 315.0110). 
4.1.23. 7-(4-Aminophenyl)-1-methyl-5-oxo-1,6-naphthyridin-
1-ium iodide (12g) 
MeI (144 mg, 1.02 mmol) was stirred with 9g (42 mg, 0.19 
mmol) in dry DMF (5 mL) for 4 d at room temperature, then at 
80°C for 2 h. The mixture was poured into EtOAc (25 mL) and 
petroleum ether (25 mL). The solid was collected, washed (pet-
roleum ether) and dried to give 12g (28 mg, 41%) as a yellow 
solid: mp >300C (decomp.); IR max 3431, 3212, 1666, 1593, 
1565 cm
-1
; 
1
H NMR  4.40 (3 H, s, Me), 6.89 (2 H, d, J = 9.0 Hz, 
Ph 3,5-H2), 7.08 (1 H, s, 8-H), 7.78 (1 H, dd, J = 7.8, 6.2 Hz, 3-
H), 7.98 (2 H, d, J = 9.1 Hz, Ph 2,6-H2), 9.03 (1 H, d, J = 7.8 Hz, 
4-H), 9.14 (1 H, d, J = 5.2 Hz, 2-H), 12.53 (1 H, br, NH); 
13
C 
NMR  44.73 (Me), 90.53 (8-C), 111.59 (Ph 3,5-C2), 117.33 (Ph 
1-C), 119.33 (3-C), 122.18 (4a-C), 129.25 (Ph 2,6-C2), 143.61 (7-
C), 148.21 (2-C), 150.70 (Ph 4-C), 151.69 (4-C), 152.58 (8a-C), 
160.61 (5-C); MS m/z 252 (M)
+
. 
4.1.24. 7-Phenyl-1,6-naphthyridin-5-one 1-oxide (13a) 
Urea.H2O2 complex (78 mg, 0.8 mmol) was added to 9a (100 
mg, 0.45 mmol) in DMF (15 mL). The mixture was cooled to 
0°C. (F3CCO)2O (189 mg, 0.9 mmol) was added dropwise. The 
mixture was stirred at 0°C for 12 h. The precipitate was collected 
and washed (water, CHCl3).The solvent was evaporated from the 
combined filtrate and washings. Chromatography (petroleum 
ether / EtOAc 1:7 → AcOH / petroleum ether / EtOAc 1:3:21) 
gave 13a (51 mg, 50%) as a white solid; mp 293-295C; IR max 
3434, 1678, 1620, 1585, 1505, 1244 cm
-1
; 
1
H NMR  7.31 (s, 8-
H), 7.41 (1 H, dd, J = 8.0, 6.5 Hz, 3-H), 7.53 (3 H, m, Ph 3,4,5-
H3), 7.83 (2 H, d, J = 8.0 Hz, Ph 2,6-H2), 7.99 (1 H, dd, J = 8.0, 
1.0 Hz, 4-H), 8.62 (1 H, dd, J = 6.5, 1.0 Hz, 2-H); 
13
C NMR  
93.77 (8-C), 121.90 (4a-C), 123.19 (3-C), 123.31 (Ph 4-C), 
127.15 (Ph 2,6-C2), 128.95 (Ph 3,5-C2), 130.29 (4-C), 137.31 (Ph 
1-C), 140.80 (7-C), 162.11 (8a-C); 
15
N NMR  252.76 (s, 1-N), 
129.56 (s, 6-N). 
4.1.25. 7-(4-Methylphenyl)-1,6-naphthyridin-5-one 1-oxide 
(13b) 
Urea.H2O2 complex (60 mg, 0.6 mmol) was added to 9b (75 
mg, 0.3 mmol) in DMF (10 mL). The mixture was cooled to 0°C. 
(F3CCO)2O (123 mg, 0.6 mmol) was added dropwise. The mix-
ture was stirred at 0°C for 12 h. The precipitate was collected and 
washed (water, Me2CO). The solvent was evaporated from the 
filtrates. Recrystallisation (EtOAc / petroleum ether) gave 13b 
(20 mg, 29%) as a white solid; mp 258-260C; IR max 3450, 
1654, 1581, 1284 cm
-1
; 
1
H NMR  2.38 (3 H, s, Me), 6.90 (1 H, 
s, 8-H), 7.32 (2 H, d, J = 8.5 Hz, Ph 3,5-H2), 7.47 (1 H, dd, J = 
8.0, 4.5 Hz, 3-H), 7.73 (2 H, d, J = 8.5 Hz, Ph 2,6-H2), 8.50 (1 H, 
dd, J = 7.5, 1.0 Hz, 4-H), 8.62 (1 H, dd, J = 4.5, 1.5 Hz, 2-H), 
11.78 (1 H, s, 6-H); 
13
C NMR  20.84 (Me), 103.99 (8-C), 121.49 
(3-C), 126.86 (Ph 2,6-C2), 129.42 (Ph 3,5-C2), 135.03 (4-C), 
154.96 (2-C); MS m/z 253.0996 (M + H)
+
, (C15H13N2O2 requires 
253.0972). 
4.1.26. 2-Phenylpyrido[2,3-d]pyrimidin-4-one (14a) 
Compound 38 (101.5 mg, 0.5 mmol), 45a (60 mg, 0.5 mmol), 
CuI (19.2 mg, 0.1 mmol) and Cs2CO3 (325 mg, 1.0 mmol) were 
stirred in DMF (5 mL) under Ar for 10 h, then at 80°C for 3 h, 
before being cooled and filtered. The evaporation residue, in 
MeOH, was filtered. The evaporation residue, in EtOAc / 
CH2Cl2, was filtered. The filtrate was washed (aq. EDTA). The 
aq. layer was extracted with CH2Cl2 (6 ) and with EtOAc (6 ). 
Drying and evaporation gave 14a (58 mg, 53%) as an off-white 
solid: mp 285-287 C (lit.
48
 mp 284-285C); 
1
H NMR (CDCl3)  
7.45 (1 H, dd, 7-H), 7.60 (5 H, m, Ph-H5), 8.41 (1 H, dd, J = 7.5, 
2.0 Hz, 8-H), 8.91 (1 H, dd, J = 4.5, 2.0 Hz, 6-H), 11.10 (1 H, br, 
NH); 
13
C NMR (CDCl3)  116.11 (8a-C), 121.48 (7C), 128.49 
(Ph 3,5-C2), 128.98 (3C), 129.10 (Ph 2,6-C2), 132.53 (Ph 4-C), 
134.06 (Ph 1-C), 140.16 (8-C), 155.49 (6-C), 159.26 (4a-C), 
166.46 (1-C); MS m/z 242.0957 (M + H2O + H)
+
 (C13H12N3O2 
requires 242.0923), 224.0835 (M + H)
+
 (C13H10N3O requires 
224.0818). 
4.1.27. 2-(4-Methylphenyl)pyrido[2,3-d]pyrimidin-4-one (14b) 
Compound 38 (101.5 mg, 0.5 mmol) was stirred with 45b (67 
mg, 0.5 mmol), CuI (19.2 mg, 0.1 mmol) and Cs2CO3 (325 mg, 
1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 10 h 
under Ar. The mixture was filtered. The evaporation residue, in 
MeOH, was filtered. The evaporation residue, in sat. aq. EDTA 
(20 mL), was kept at 2-8 °C for 30 min and the solid was collec-
ted. The solid was washed (petroleum ether, water) and was dried 
to give 14b (41 mg, 35%) as a white powder: mp 249-251°C, 
1
H 
NMR  2.47 (3 H, s, Me), 7.28 (1 H, dd, J = 7.4, 5.1 Hz, 6-H), 
7.48 (2 H, d, J = 8.1 Hz, Ph 3,5-H2), 7.94 (2 H, d, J = 8.1 Hz, Ph 
2,6-H2), 8.44 (1 H, d, J = 7.5 Hz, 5-H), 8.48 (1 H, d, J = 4.7 Hz, 
7-H), 11.09 (1 H, br, NH); 
13
C NMR  20.99 (Me), 119.07 (4a-
C), 119.84 (6-C), 127.31 (Ph 3,5-C2), 129.53 (Ph 1-C), 129.61 
(Ph 2,6-C2), 140.15 (5-C), 142.84 (Ph 4-C), 148.29 (7-C), 155.60 
(8a-C), 159.67 (2-C), 166.78 (4-C); MS m/z 236.0836 (M - H)
-
 
(C14H10N3O requires 236.0824). 
4.1.28. 2-(4-Trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-
one (14d) 
Compound 38 (101.5 mg, 0.5 mmol) was stirred with 45d (94 
mg, 0.5 mmol), CuI (19.2 mg, 0.1 mmol) and Cs2CO3 (325 mg, 
1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 10 h 
under Ar. The mixture was filtered. The evaporation residue, in 
MeOH, was filtered. The evaporation residue was treated with 
sat. aq. EDTA (20 mL) at 2-8 °C for 30 min. The solid was col-
lected, washed (petroleum ether, water) and dried to give 14d (64 
mg, 45%) as a white powder: mp 254-256C; 
1
H NMR  7.29 (1 
H, dd, J = 6.8, 4.0 Hz, 6-H), 8.04 (2 H, m, Ph 2,6-H2), 8.22 (2 H, 
m, Ph 3,5-H2), 8.46 (1 H, d, J = 7.0 Hz, 5-H), 8.54 (1 H, d, J = 
4.0 Hz, 7-H), 11.01 (1 H, br, NH); 
13
C NMR  119.0 (6-C), 
126.10 (Ph 2,6-C2), 128.22 (q J = 2.7 Hz, Ph 3,5-C2), 140.10 (5-
C), 149.5 (7-C); 
19
F NMR  -61.35 (CF3); MS 292.0699 (M + 
H)
+
 (C14H9F3N3O requires 292.0692). 
4.1.29. 2-(4-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-one (14e) 
Compound 38 (101.5 mg, 0.5 mmol) was stirred with 45e (77 
mg, 0.5 mmol), CuI (19.2 mg, 0.1 mmol) and Cs2CO3 (325 mg, 
1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 10 h 
under Ar. The mixture was filtered. The evaporation residue, in 
MeOH, was filtered. The evaporation residue was treated with 
sat. aq. EDTA (20 mL) at 2-8 °C for 30 min. The solid was coll-
ected and recrystallised (EtOAc / CH2Cl2) to give 14e (10 mg, 
8%) as a pale grey powder: mp 266-268C (lit.
49
 mp 300.5C); 
1
H NMR  7.25 (1 H, m, 6-H), 7.73 (2 H, d, J = 8.9 Hz, Ph 2,6-
H2), 8.06 (2 H, d, J = 8.9 Hz, Ph 3,5-H2), 8.42 (1 H, m, 5-H), 8.45 
(1 H, m, 7-H), 11.10 (1 H, br NH); 
13
C NMR  119.30 (4a-C), 
119.75 (6-C), 129.27 (Ph 3,5-C2), 129.50 (Ph 2,6-C2), 132.0 (Ph 
1-C), 137.0 (Ph 4-C), 140.25 (5-C), 149.34 (7-C), 151.0 (8a-C), 
156.99 (2-C), 160.15 (1-C); MS m/z 537.0621 (2 M + Na)
+
 
(C26H16
35
Cl2N6NaO2 requires 537.0598), 282.0225 (M + Na)
+
 
(C13H8
37
ClN3NaO requires 282.0224), 280.0257 (M + Na)
+
 
(C13H8
35
ClN3NaO requires 280.0254). 
4.1.30. 2-Phenylpyrido[3,4-d]pyrimidin-4-one (15a) 
Compound 31 (101.5 mg, 0.50 mmol) was stirred with 45a 
(60 mg, 0.50 mmol), CuI (19 mg, 0.10 mmol) and Cs2CO3 (325 
mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 
12 h under Ar. The evaporation residue, in MeOH, was filtered. 
The evaporation residue, in sat. aq. EDTA (20 mL), was sonic-
ated for 5 min. The solution was kept at 2-8C for 1 h. The solid 
was collected. The filtrate was extracted with EtOAc (4 ×). The 
combined extracts were dried and the solvent was evaporated. 
Washing (water, petroleum ether) and drying gave 15a (14 mg, 
13%) as a white powder: mp 228-230°C (lit.
50
 mp 266-267C); 
1
H NMR  7.62 (3 H, m, Ph 3,4,5-H3), 8.02 (1 H, d, J = 5.0 Hz, 
5-H), 8.26 (2 H, d, J = 6.9 Hz, Ph 2,6-H2), 8.68 (1 H, d, J = 5.0 
Hz, 6-H), 9.16 (1 H, s, 8-H), 10.40 (1 H, br, NH); 
13
C NMR  
118.09 (5-C), 127.42 (Ph 1-C), 127.93 (Ph 2,6-C2), 128.97 (Ph 
3,5-C2), 129. 04 (4a-C), 131.56 (8a-C), 132.99 (Ph 4-C), 145.44 
(6-C), 150.70 (8-C), 155.07 (2-C), 162.13 (4-C); MS m/z 
469.1398 (2 M + Na)
+
 (C26H18N6NaO2 requires 469.1384), 
246.0638 (M + Na)
+
 (C13H9N3NaO requires 246.0641). 
4.1.31. 2-(4-Methylphenyl)pyrido[3,4-d]pyrimidin-4-one (15b) 
Compound 31 (101.5 mg, 0.50 mmol) was stirred with 45b 
(67 mg, 0.50 mmol), CuI (19 mg, 0.10 mmol) and Cs2CO3 (325 
mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 
12 h under Ar. The evaporation residue, in MeOH, was filtered. 
The evaporation residue, in sat. aq. EDTA (20 mL), was extrac-
ted thrice with CH2Cl2. Drying and evaporation gave 15b (10 mg, 
9%) as a white powder: mp 214-216°C, 
1
H NMR  2.44 (3 H, s, 
Me), 7.36 (2 H, d, J = 8.1 Hz, Ph 3,5-H2), 7.91 (1 H, d, J = 5.2 
Hz, 5-H), 8.24 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.52 (1 H, d, J = 
5.2 Hz, 6-H), 9.03 (1 H, s, 7-H), 10.20 (1 H, br, NH); 
13
C NMR  
20.97 (Me), 118.16 (5-C), 126.00 (4a-C), 127.47 (Ph 1-C), 
127.47 (Ph 2,6-C2), 128.85 (Ph 3,5-C2), 129.45 (Ph 4-C), 144.00 
(6-C), 149.00 (8a-C), 150.40 (8-C), 168.90 (2-C); MS m/z 
236.0836 (M - H)
-
 (C14H10N3O requires 236.0824). 
4.1.32. 2-(4-Trifluoromethylphenyl)pyrido[3,4-d]pyrimidin-4-
one (15d) 
Compound 31 (101.5 mg, 0.50 mmol) was stirred with 45d 
(94 mg, 0.5 mmol), CuI (19.2 mmol, 0.1 mmol) and Cs2CO3 (325 
mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20C for 
10 h under Ar. The mixture was filtered. The evaporation residue 
was suspended in MeOH and the suspension was filtered. The 
evaporation residue, sat. aq. EDTA (20 mL) was kept at 2-8°C 
for 1 h and the solid was collected. The filtrate was extracted 
with EtOAc (6 ). The combined extracts were dried and the sol-
vent was evaporated. Washing (petroleum ether, water) and 
drying gave 15d (34 mg, 24%) as an off-white powder: mp > 
300C (decomp.); 
1
H NMR  7.87 (2 H, d, J = 8.3 Hz, Ph 2,6-
H2), 8.12 (1 H, m, 5-H), 8.43 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 8.71 
(1 H, br, 6-H), 9.23 (1 H, br, 8-H), 13.10 (1 H, br, NH); 
13
C NMR 
 125.24 (q, J = 289.3 Hz, CF3), 125.56 (q, J = 2.3 Hz, Ph 3,5-
C2), 128.91 (Ph 2,6-C2), 131.5 (4a-C), 136.27 (q, J = 31.7 Hz, Ph 
4-C), 138.0 (Ph 1-C), 147.0 (5-C), 149.0 (8-C), 154.0 (2-C), 
155.5 (6-C), 158.0 (8a-C), 161.32 (4-C); MS m/z 314 (M + Na)
+
, 
292.0705 (M + H)
+
 (C14H9F3N3O requires 292.0692). 
4.1.33. 2-Phenylpyrido[4,3-d]pyrimidin-4-one (16a) 
Compound 37 (101.5 mg, 0.5 mmol) was stirred with 45a (60 
mg, 0.5 mmol), CuI (19.2 mg, 0.1 mmol) and Cs2CO3 (325 mg, 
1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 50°C for 10 h 
under Ar. The mixture was filtered. The evaporation residue was 
suspended in MeOH and filtered. The evaporation residue, in sat. 
aq. EDTA (20 mL), was sonicated for 5 min. This mixture was 
extracted with EtOAc (6 ). Drying and evaporation gave 16a 
(50 mg, 44%) as an off-white powder: mp 273-275°C (lit.
51
 284-
286°C), 
1
H NMR  7.61 (1 H, m, 8-H), 7.63 (3 H, m, Ph 3,4,5-
H3), 8.28 (2 H, d, J = 7.2 Hz, Ph 2,6-H2), 8.83 (1 H, br, 7-H), 
9.33 (1 H, br, 5-H), 12.80 (1 H, br, NH); 
13
C NMR  117.5 (4a-
C), 120.0 (8-C), 124.0 (Ph 1-C), 128.26 (Ph 3,5-C2), 128.64 (Ph 
2,6-C2), 132.0 (Ph 4-C), 135.0 (3-C), 149.0 (5-C), 152.0 (7-C), 
156.0 (8a-C), 162.0 (4-C); MS m/z 469.1396 (2 M + Na)
+
 
(C26H18N6NaO2 requires 469.1389), 246.0644 (M + Na)
+
 
(C13H9N3NaO requires 246.0643), 224.0828 (M + H)
+
 
(C13H10N3O requires 224.0818). 
4.1.34. 2-(4-Methylphenyl)pyrido[4,3-d]pyrimidin-4-one (16b) 
Compound 37 (101.5 mg, 0.5 mmol) was stirred with 45b (67 
mg, 0.5 mmol), CuI (19.2 mmol, 0.1 mmol) and Cs2CO3 (325 
mg, 1.0 mmol) in DMF (5 mL) at 80°C for 12 h under Ar. The 
mixture was filtered. The evaporation residue was suspended in 
MeOH and filtered. The evaporation residue, in sat. aq. EDTA 
(20 mL), was extracted with EtOAc (6 ). Drying and evapor-
ation gave 16b (46 mg, 42%) as an off-white powder: mp 276-
278C (lit.
51
 296-299C); 
1
H NMR  2.45 (3 H, s, Me), 7.29 (2 H, 
d, J = 8.0 Hz, Ph 3,5-H2), 7.64 (1 H, d, J = 5.4 Hz, 5-H), 8.18 (2 
H, d, J = 8.2 Hz, Ph 2,6-H2), 8.85 (1 H, br, 6-H), 9.33 (1 H, br, 8-
H); 
13
C NMR  21.0 (Me), 120.12 (8a-C), 120.39 (5-C), 128.17 
(Ph 2,6-C2), 129.21 (Ph 3,5-C2), 129.82 (Ph 1-C), 131.48 (Ph 4-
C), 142.27 (3-C), 149.45 (8-C), 157.37 (4a-C), 162.37 (1-C); MS 
m/z 238.0984 (M + H)
+
 (C14H12N3O requires 238.0980). 
4.1.35. 2-(4-Trifluoromethylphenyl)pyrido[4,3-d]pyrimidin-4-
one (16d) 
Compound 37 (101.5 mg, 0.5 mmol) was stirred with 45d (94 
mg, 0.5 mmol), CuI (19.2 mmol, 0.1 mmol) and Cs2CO3 (325 
mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20C for 
10 h under Ar. The mixture was filtered. The evaporation residue 
was suspended in MeOH. The suspension was filtered. The evap-
oration residue, in sat. aq. EDTA, was kept at 2-8 °C for 1 h and 
the solid was collected. The filtrate was extracted with EtOAc (6 
). The extracts were dried and the solvent was evaporated. 
Washing (petroleum ether, water) and drying gave 16d (70 mg, 
50%) as an off-white powder: mp 267-268C; 
1
H NMR  7.71 (1 
H, d, J = 4.4 Hz, 8-H), 8.00 (2 H, d, J = 8.3 Hz, Ph 2,6-H2), 8.44 
(2 H, d, J = 8.2 Hz, Ph 3,5-H2), 9.08 (1 H, br, 7-H), 9.38 (1 H, br, 
5-H), 13.10 (1 H, br, NH); 
13
C NMR  122.04 (8a-C), 125.21 (8-
C), 125.24 (Ph 2,6-C2), 125.51 (q, J = 3.5 Hz, Ph 3,5-C2), 129.17 
(6-C), 131.76 (q, J = 340.6 Hz, CF3), 134.0 (q, J = 27.5 Hz, Ph 4-
C), 138.0 (Ph 1-C), 149.53 (5-C), 153.49 (4a-C), 156.32 (3-C), 
162.0 (1-C); 
19
F NMR  -61.34 (s, CF3); MS m/z 605 (2 M + 
Na)
+
, 314.0496 (M + Na)
+
 (C14H8F3N3NaO requires 314.0517), 
292.0702 (M + H)
+
 (C14H9F3N3O requires 292.0698). 
4.1.36. 2-(4-Chlorophenyl)pyrido[4,3-d]pyrimidin-4-one (16e) 
Compound 37 (101.5 mg, 0.5 mmol) was stirred with 45e 
(77.3 mg, 0.5 mmol), CuI (19.2 mmol, 0.1 mmol) and Cs2CO3 
(325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 12 h under Ar. 
The mixture was filtered. The evaporation residue, in MeOH, 
was filtered. The evaporation residue, in sat. aq. EDTA (20 mL), 
was extracted with EtOAc (6 ). The combined extracts were 
dried. The evaporation residue was washed (petroleum ether, 
water) and dried to give 16e (17 mg, 13%) as a white powder: mp 
>300 (decomp.); 
1
H NMR  7.66 (1 H, d, J = 5.6 Hz, 5-H), 7.69 
(2 H, d, J = 8.6 Hz, Ph 2,6-H2), 8.29 (2 H, d, J = 8.6 Hz, Ph 3,5-
H2), 8.86 (1 H, d, J = 5.5 Hz, 6-H), 9.34 (1 H, br, 8-H), 13.05 (1 
H, br, NH); 
13
C NMR  120.0 (5-C), 126.50 (8a-C), 128.78 (Ph 
3,5-C2), 130.09 (Ph 2,6-C2), 131.02 (Ph 4-C), 137.15 (Ph 1-C), 
146.0 (4-C), 153.52 (8-C), 155.99 (3-C), 162.0 (1-C); MS m/z 
282.0269 (M + Na)
+
 (requires 282.0224), 280.0260 (M + Na)
+
 
(C13H8
35
ClN3NaO requires 280.0254). 
4.1.37. 1-Methyl-7-phenyl-1,2,3,4-tetrahydro-1,6-naphthyrid-
in-5-one (17a) 
BH3.pyridine complex (60 mL) was added to 12a (80 mg, 0.22 
mmol) in HCO2H (5 mL) at 0C was and the mixture was stirred 
for 5 d at 20C. Daily, additional BH3.pyridine (10 mL) was 
added. Evaporation, trituration (MeOH; 10 mL) and recrystallis-
ation (Pr
i
OH) gave 17a (21 mg, 20%) as a pale grey solid: mp 
315-317C; IR max 1655, 1620 cm
-1
; 
1
H NMR (CDCl3)  1.89 (2 
H, m, 3-H2), 2.51 (2 H, m, 4-H2), 3.11 (3 H, s, Me), 3.36 (2 H, m, 
2-H2), 6.30 (1 H, s, 8-H), 7.43 (3 H, m, Ph 3,4,5-H3), 7.68 (2 H, 
m, Ph 2,6-H2); 
13
C NMR (CDCl3)  19.59 (4-C), 20.12 (Me), 
50.78 (2-C), 96.80 (8-C), 100.22 (4a-C), 126.58 (Ph 2,6-C2), 
129.25 (Ph 3,5-C2), 130.47 (4-C), 132.79 (Ph 1-C), 144.28 (7-C), 
155.00 (8a-C), 158.96 (5-C); MS m/z 503 (2 M + Na)
+
, 263.1177 
(M + Na) (C15H16N2NaO requires 263.1160). 
4.1.38. 7-(4-Methoxyphenyl)-1-methyl-1,2,3,4-tetrahydro-1,6-
naphthyridin-5-one (17c) 
BH3.Py complex (0.10 mL) was added dropwise to 12c (50 
mg, 0.13 mmol) in HCO2H (5 mL) at 0C and the mixture was 
stirred at 20C for 5 d. Daily, additional BH3.Py (0.01 mL) was 
added. The evaporation residue, in AcOH (2 mL), was diluted 
with water (10 mL). The mixture was extracted (EtOAc, 3×). 
Evaporation and recrystallisation (water) gave 17c (1.0 mg, 3%) 
as a white powder: mp 221-223ºC; 
1
H NMR (CDCl3)  1.93 (2 H, 
qn, J = 6.2 Hz, 3-H2), 2.61 (2 H, t, J = 6.4 Hz, 4-H2), 3.02 (3 H, s, 
NMe), 3.28 (2 H, t, J = 5.4 Hz, 2-H2), 3.85 (3 H, s, OMe), 5.98 (1 
H, s, 8-H), 6.96 (2 H, d, J = 8.9 Hz, Ph 3,5-H2), 7.47 (2 H, d, J = 
8.9 Hz, Ph 2,6-H2); 
13
C NMR (CDCl3)  20.60 (4-C), 20.83 (3-
C), 38.81 (NMe), 50.79 (2-C), 55.44 (OMe), 94.01 (8-C), 100.49 
(4a-C), 114.62 (Ph 3,5-C2), 126.95 (Ph 1-C), 127.18 (Ph 2,6-C2), 
142.51 (Ph 4-C), 153.33 (8a-C), 160.67 (7-C), 162.28 (5-C); MS 
m/z 563 (2 M + Na)
+
, 541 (2 M + H)
+
, 293.1259 (M + Na)
+
 
(C16H18N2NaO2 requires 293.1266), 271.1452 (M + H)
+
 
(C16H19N2O2 requires 271.1447). 
4.1.39. 1-Methyl-7-(4-trifluoromethylphenyl)-1,2,3,4-tetra-
hydro-1,6-naphthyridin-5-one (17d) 
BH3.Py complex (0.10 mL) was added dropwise to 12d (30 
mg, 0.07 mmol) in HCOOH (5 mL) at 0C. The mixture was 
stirred for 10 d at 20C. Each day, additional BH3.Py (0.01 mL) 
was added. The evaporation residue, in water (5 mL), was sonic-
ated. The precipitate was collected and recrystallised (water) to 
give 17d (5.0 mg, 24%) as a white powder: mp 287-288ºC; 
1
H 
NMR (CDCl3)  1.94 (2 H, qn, J = 5.5 Hz, 3-H2), 2.63 (2 H, t, J 
= 6.0 Hz, 4-H2), 3.31 (2 H, t, J = 5.5 Hz, 2-H2), 6.09 (1 H, s, 8-
H), 7.67 (2 H, d, J = 8.5 Hz, Ph 2,6-H2), 7.72 (2 H, d, J = 8.5 Hz, 
Ph 3,5-H2); 
13
C NMR (CDCl3)  20.61 (4-C), 20.94 (3-C), 50.01 
(2-C), 96.10 (8-C), 101.76 (4a-C), 125.10 (q, J = 275 Hz, CF3), 
126.38 (m, Ph 2,3,5,6-C4), 131.95 (q, J = 37.5 Hz, Ph 4-C), 
140.02 (Ph 1-C), 141.80 (7-C), 149.10 (5-C), 157.22 (8a-C); 
19
F 
NMR (CDCl3)  -62.79 (CF3); MS m/z 639.2179 (2 M + Na)
+
 
(C32H30F6N4NaO2 requires 639.2171), 617.2372 (2 M + H)
+
 
(C32H31F6N4O2 requires 617.2351), 331.1061 (M + Na)
+
 
(C16H15F3N2NaO requires 331.1034), 309.1239 (M + H)
+
 
(C16H16F3N2O requires 309.1215). 
4.1.40. 7-(4-Chlorophenyl)-1-methyl-1,2,3,4-tetrahydro-1,6-
naphthyridin-5-one (17e) 
Compound 12e was treated with BH3.Py complex, as for the 
synthesis of 17d, to give 17e (44%) as a white powder: mp 195-
197ºC; 
1
H NMR (CDCl3)  1.95 (2 H, qn, J = 6.4 Hz, 3-H2), 2.60 
(2 H, t, J = 6.4 Hz, 4-H2), 3.04 (3 H, s, NMe), 3.30 (2 H, t, J = 
5.6 Hz, 2-H2), 6.06 (1 H, s, 8-H), 7.43 (2 H, d, J = 8.6 Hz, Ph 3,5-
H2), 7.54 (2 H, d, J = 8.7 Hz, Ph 2,6-H2); 
13
C NMR (CDCl3)  
20.62 (4-C), 20.83 (3-C), 38.76 (NMe), 50.43 (2-C), 95.28 (8-C), 
101.97 (4a-C), 127.54 (Ph 2,6-C2), 129.33 (Ph 3,5-C2), 134.29 
(Ph 1-C), 137.70 (Ph 4-C), 142.30 (7-C), 153.97 (8a-C), 157.50 
(5-C); MS m/z 549.1819 (2 M + H)
+
 (C30H31
35
ClN2O requires 
549.1824), 275.0941 (M + H)
+
 (C15H16
35
ClN2O requires 
275.0946). 
4.1.41. 7-(4-Bromophenyl)-1-methyl-1,2,3,4-tetrahydro-1,6-
naphthyridin-5-one (17f) 
Compound 12f was treated with BH3.Py complex, as for the 
synthesis of 17d, to give 17f (47%) as a white powder: mp 205-
207 ºC; 
1
H NMR (CDCl3)  1.95 (2 H, qn, J = 6.4 Hz, 3-H2), 2.61 
(2 H, t, J = 6.3 Hz, 4-H2), 3.29 (3 H, s, Me), 3.29 (2 H, t, J = 5.5 
Hz, 2-H2), 6.02 (1 H, s, 8-H), 7.42 (2 H, d, J = 8.7 Hz, Ph 2,6-
H2), 7.59 (2 H, d, J = 8.7 Hz, Ph 3,5-H2); 
13
C NMR (CDCl3)  
20.75 (4-C), 21.63 (3-C), 38.70 (NMe), 50.76 (2-C), 94.44 (8-C), 
101.46 (4a-C),123.93 (Ph 4-C), 127.41 (Ph 2,6-C2), 132.27 (Ph 
3,5-C2), 133.39 (Ph 1-C), 141.80 (7-C), 153.16 (8a-C), 162.35 (5-
C); MS m/z 663 / 661 / 659 (2 M + Na)
+
, 641 / 639 / 637 (2 M + 
H)
+
, 343.0249 (M + Na)
+
 (C15H15
81
BrN2NaO requires 343.0246), 
341.0264 (M + Na)
+
 (C15H15
79
BrN2NaO requires 341.0266), 
321.0426 (M + H)
+
 (C15H16
81
BrN2O requires 321.0426), 
319.0448 (M + H)
+
 (C15H16
79
BrN2O requires 319.0446). 
4.1.42. 4-Oxo-2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrim-
idinium formate (18a) 
Compound 47a (50 mg, 0.16 mmol) was stirred with Pd/C 
(10%, 50 mg) in dry MeOH (10 mL) and HCO2H (1.0 mL) for 10 
h under Ar. Filtration (Celite
®
) and evaporation gave 18a (32 mg, 
89%) as an off-white powder: mp 244-245°C (decomp.) (lit.
52
 
214-216°C for free base); 
1
H NMR  2.46 (2 H, m, 8-H2), 3.20 (2 
H, m, 7-H2), 3.79 (2 H, s, 5-H2), 7.59 (3 H, m, Ph 3,4,5-H3), 8.14 
(2 H, d, J = 7.2 Hz, Ph 2,6-H2), 9.25 (2 H, br, 3-NH, 7-NH); 
13
C 
NMR  29.50 (8-C), 40.12 (5-C), 41.02 (7-C), 127.56 (Ph 3,5-
C2), 128.58 (Ph 2,6-C2), 131.37 (Ph 4-C), 132.55 (Ph 1-C), 
154.78 (4a-C), 158.03 (8a-C), 161.93 (2-C), 164.65 (4-C); MS 
m/z 477.2029 (2 M + Na)
+
 (C26H26N6NaO2 requires 477.2015), 
250.0947 (M + Na)
+
 (C13H13N3NaO requires 250.0956), 
228.1169 (M + H)
+
 (C13H14N3O requires 228.1137). 
4.1.43. 2-(4-Methylphenyl)-4-oxo-5,6,7,8-tetrahydropyrido-
[4,3-d]pyrimidinium formate (18b) 
Compound 47b was treated with Pd/C and HCO2H in MeOH, 
as for the synthesis of 18a, to give 18b (86%) as an off-white 
powder: mp 279-280°C; 
1
H NMR  2.42 (3 H, s, Me), 2.45 (2 H, 
m, 8-H2), 2.73 (2 H, m, 7-H2), 3.33 (2 H, s, 5-H2), 7.36 (2 H, d, J 
= 7.9 Hz, Ph 3,5-H2), 8.03 (2 H, d, J = 8.0 Hz, Ph 2,6-H2), 8.31 (2 
H, br, 3-NH, 7-NH); 
13
C NMR  20.94 (Me), 31.04 (7-C), 45.09 
(8-C), 46.03 (5-C), 116.91 (4a-C), 127.45 (Ph 2,6-C2), 129.16 
(Ph 3,5-C2), 129.50 (Ph 1-C), 141.41 (Ph 4-C), 154.08 (2-C), 
158.07 (8a-C), 161.47 (4-C); MS m/z 242.1294 (M + H)
+
 
(C14H16N3O requires 242.1288). 
4.1.44. 4-Oxo-2-(4-trifluoromethylphenyl)-5,6,7,8-tetrahydro-
pyrido[4,3-d]pyrimidinium formate (18d) 
Compound 47d (was treated with Pd/C and HCO2H in MeOH, 
as for the synthesis of 18a, to give 18d (68%) as an off-white 
powder: mp 280-281°C (decomp.); 
1
H NMR  2.32 (2 H, m, 8-
H2), 2.55 (2 H, m, 7-H2), 3.13 (2 H, s, 5-H2), 7.66 (2 H, d, J = 8.5 
Hz, Ph 3,5-H2), 8.43 (2 H, d, J = 8 Hz, Ph 2,6-H2); 
13
C NMR  
31.52 (7-C), 46.07 (8-C), 53.41 (5-C), 114.42 (4a-C), 123.57 (q, 
J = 270.1 Hz, CF3), 124.40 (q, J = 3.6 Hz, Ph 3,5-C2), 127.77 (Ph 
2,6-C2), 128.41 (q, J = 31.1 Hz, Ph 4-C), 144.78 (Ph 1-C), 155.98 
(8a-C), 156.99 (4-C), 159.29 (2-C); 
19
F NMR  -60.69 (s, CF3); 
MS m/z 296.1016 (M + H)
+
 (C14H13F3N3O requires 296.1005). 
4.1.45. 2-(4-Phenylethynylphenyl)-5,6,7,8-tetrahydropyrido-
[4,3-d]pyrimidin-4-one hydrochloride (18j) 
Compound 47j (170 mg, 0.41 mmol) was stirred for 10 h with 
Pd/C (10%, 200 mg) in dry MeOH (10 mL) and HCOOH (1.0 
mL). The mixture was filtered through Celite
®
. The evaporation 
residue was recrystallised (EtOH). The formate salt was treated 
with HCl in dioxane (4.0 M, 3.0 mL) and Et2O (5 mL). The 
precipitate was collected and washed (petroleum ether) to give 
18j (44 mg, 34%) as a white crystalline powder: mp >260°C 
(decomp.); 
1
H NMR  2.92-2.95 (4 H, m, 7,8-H4), 4.02-4.04 (2 
H, m, 5-H2), 7.24 (1 H, m, Ph’ 4-H), 7.28 (2 H, d, J = 7.3 Hz, Ph 
3,5-H2), 7.30-7.35 (4 H, m, Ph’ 2,3,5,6-H4), 7.41 (2 H, d, J = 8.1 
Hz, Ph 2,6-H2), 8.26 (2 H, br, +NH2); 
13
C NMR  36.52 (8-C), 
36.86 (7-C), 41.88 (5-C), 66.32 (ethynyl 1-C), 92.21 (ethynyl 2-
C), 128.21 (Ph’ 3,5-C2), 128.33 (Ph 3,5-C2), 128.37 (Ph 4-C), 
128.53 (Ph’ 2,6-C2), 128.68 (Ph’ 1-C), 128.77 (Ph 1-C), 128.86 
(Ph 2,6-C2), 131.49 (4a-C), 141.29 (8a-C), 141.82 (2-C), 167.31 
(4-C); MS m/z 350.1263 (M + Na)
+
 (C21H17N3NaO requires 
350.1269). 
4.1.46. 4-Oxo-2-(pyridin-4-yl)-5,6,7,8-tetrahydropyrido[4,3-
d]pyrimidinium formate (18l) 
Compound 47l was treated with Pd/C and HCO2H in MeOH, 
as for the synthesis of 18a, to give 18l (80%) as an off-white 
powder: mp 242-244°C (lit.
52
 244-246ºC); 
1
H NMR  3.02 (2 H, 
m, 8-H2), 3.27 (2 H, m, 7-H2), 3.44 (2 H, s, 5-H2), 7.16 (2 H, d, J 
= 8.2 Hz, Py 2,6-H2), 7.53 (2 H, d, J = 8.1 Hz, Py 3,5-H2); 
13
C 
NMR  31.14 (7-C), 45.32 (8-C), 50.61 (5-C), 116.89 (4a-C), 
117.21 (Py 1-C), 125.53 (Py 2,6-C2), 128.10 (Py 3,5-C2), 156.85 
(8a-C), 160.38 (4-C), 161.20 (2-C). 
4.1.47. 3-Cyano-2-phenylethynylpyridine (25a) 
Compound 24 (150 mg, 0.80 mmol) in THF (5 mL) was 
stirred with CuI (15.2 mg, 80 mmol) and (Ph3P)2PdCl2 (28 mg, 40 
mmol) in Pr
i
2NH (5 mL) under Ar at 45°C for 30 min. Phenyleth-
yne 21a (163 mg, 1.6 mmol) was added. The mixture was stirred 
at 40°C for 5 d. Evaporation and chromatography (petroleum 
ether / EtOAc 3:1) gave 25a (80 mg, 50%) as a pale buff powder: 
mp 83-85C (lit.
53
 mp 85-87C); 
1
H NMR (CDCl3)  7.33 (1 H, 
dd, J = 8.0, 4.8 Hz, 5-H), 7.40 (3 H, m, Ph 3,4,5-H3), 7.68 (d, J = 
7.6 Hz, Ph 2,6-H2), 7.95 (1 H, dd, J = 8.0, 2.0 Hz, 4-H), 8.77 (1 
H, dd, J = 4.8, 1.6 Hz, 6-H); 
13
C NMR (CDCl3)  85.62 (ethyne 
2-C), 96.20 (ethyne 1-C), 112.82 (3-C), 115.91 (C≡N), 120.98 
(5-C), 121.87 (Ph 1-C), 128.47 (Ph 3,5-C2), 129.99 (Ph 4-C), 
132.47 (Ph 2,6-C2), 139.76 (4-C), 146.04 (2-C), 152.77 (6-C); 
MS m/z 227.0575 (M + Na)
+
 (C14H8N2Na requires 227.0586), 
205.0755 (M + H)
+
 (C14H9N2 requires 205.0766). 
4.1.48. 3-Cyano-2-(4-methylphenylethynyl)pyridine (25b) 
1-Ethynyl-4-methylbenzene 21b was treated with 24, CuI, Na 
ascorbate and (Ph3P)2PdCl2 in Pr
i
2NH and THF, as for the syn-
thesis of 25a, except that the chromatographic eluent was petrol-
eum ether / EtOAc (5:1 → 3:1), to give 25b (80%) as a pale buff 
powder: mp 175-178C; 
1
H NMR (CDCl3)  2.40 (3 H, s, Me), 
7.21 (2 H, J = 8.2 Hz, Ph 3,5-H2), 7.33 (1 H, dd, J = 8.0, 4.9 Hz, 
5-H), 7.59 (2 H, d, J = 8.1 Hz, Ph 2,6-H2), 7.97 (1 H, dd, J = 8.0, 
1.8 Hz, 4-H), 8.78 (1 H, dd, J = 4.9, 1.7 Hz, 6-H); 
13
C NMR 
(CDCl3)  21.70 (Me), 112.66 (2-C), 121.73 (5-C), 129.32 (Ph 
3,5-C2), 132.50 (Ph 2,6-C2), 139.84 (4-C), 140.61 (Ph 4-C), 152.8 
(6-C); MS m/z 241.0709 (M + Na)
+
 (C15H9N2Na requires 
241.0742), 219.0905 (M + H)
+
 (C15H11N2 requires 219.0922). 
4.1.48. 3-Cyano-2-(4-methoxyphenylethynyl)pyridine (25c) 
Compound 21c was treated with 24, CuI, Na ascorbate and 
(Ph3P)2PdCl2 in Pr
i
2NH and THF, as for the synthesis of 25b, to 
give 25c (81%) as a pale buff powder: mp 118-120C; 
1
H NMR 
(CDCl3)  3.83 (3 H, s, Me), 6.90 (2 H, d, J = 8.9 Hz, Ph 3,5-H2), 
7.30 (1 H, dd, J = 8.0, 4.9 Hz, 5-H), 7.62 (2 H, d, J = 8.9 Hz, Ph 
2,6-H2), 7.93 (1 H, dd, J = 8.2, 2.1 Hz, 4-H), 8.75 (1 H, dd, J = 
4.9, 1.7 Hz, 6-H); 
13
C NMR  55.32 (Me), 85.01 (ethyne 2-C), 
96.94 (ethyne 1-C), 112.94 (5-C), 114.22 (Ph 3,5-C2), 116.09 
(C≡N), 121.45 (3-C), 134.23 (Ph 2,6-C2), 139.74 (4-C), 146.36 
(6-C), 152.74 (2-C), 161.05 (Ph 4-C); MS m/z 257.0695 (M + 
Na)
+
 (C15H10N2NaO requires 257.0690). 
4.1.50. 3-Cyano-2-(4-trifluoromethylphenylethynyl)pyridine 
(25d) 
Compound 21d was treated with 24, CuI, Na ascorbate and 
(Ph3P)2PdCl2 in Pr
i
2NH and THF, as for the synthesis of 25b, to 
give 25d (55%) as a pale buff powder: mp 129-132C; 
1
H NMR 
(CDCl3)  7.40 (1 H, dd, J = 7.9, 4.9 Hz, 5-H), 7.66 (2 H, d, J = 
8.0 Hz, Ph 3,5-H2), 7.79 (2 H, d, J = 8.0 Hz, Ph 2,6-H2), 8.00 (1 
H, dd, J = 8.0, 1.8 Hz, 4-H), 8.81 (1 H, dd, J = 4.9, 1.8 Hz, 6-H); 
13
C NMR (CDCl3)  87.25 (ethyne 2-C), 94.03 (ethyne 1-C), 
113.22 (3-C), 115.78 (C≡N), 122.50 (5-C), 123 (CF3), 124.73 (Ph 
1-C), 125.49 (q, J = 3.6 Hz, Ph 3,5-C2), 131.8 (q, J = ca. 30 Hz, 
Ph 4-C), 132.75 (Ph 2,6-C2), 139.87 (4-C), 145.48 (2-C), 152.95 
(6-C); 
19
F NMR (CDCl3)  -63.03 (s, CF3); MS m/z 295.0428 (M 
+ Na)
+
 (C15H7F3N2Na requires 295.0459), 273.0622 (M + H)
+
 
(C15H8N2F3 requires 273.0640). 
4.1.51. 2-(4-Chlorophenylethynyl)-3-cyanopyridine (25e) 
Compound 21e was treated with 24, CuI, Na ascorbate and 
(Ph3P)2PdCl2 in Pr
i
2NH and THF, as for the synthesis of 25b, to 
give 25e (42%) as an amber powder: mp 84-86C; 
1
H NMR 
(CDCl3)  7.36 (1 H, dd, J = 7.9, 4.8 Hz, 5-H), 7.37 (2 H, d, J = 
8.7 Hz, Ph 3,5-H2), 7.61 (2 H, d, J = 8.7 Hz, Ph 2,6-H2), 7.98 (1 
H, dd, J = 7.9, 1.7 Hz, 4-H), 8.79 (1 H, dd, J = 5.0, 1.7 Hz, 6-H); 
13
C NMR (CDCl3)  86.38 (ethyne 2-C), 94.80 (ethyne 1-C), 
112.87 (3-C), 115.82 (C≡N), 119.43 (Ph 1-C), 122.31 (5-C), 
128.92 (Ph 3,5-C2), 133.63 (Ph 2,6-C2), 136.30 (Ph 4-C), 139.77 
(4-C), 145.75 (2-C), 152.85 (6-C); MS m/z 239.0353 (M + H)
+
 
(C14H8
35
ClN2H requires 239.0376). 
4.1.52. 2-(4-Aminophenylethynyl)-3-cyanopyridine (25g) 
Compound 21g was treated with 24, CuI, Na ascorbate and 
(Ph3P)2PdCl2 in Pr
i
2NH and THF, as for the synthesis of 25b, to 
give 25g (364 mg, 87%), as a dark green powder: mp 128-130C; 
1
H NMR (CDCl3)  3.96 (2 H, br, NH2), 6.64 (2 H, d, J = 9.1 Hz, 
Ph 3,5-H2), 7.30 (1 H, dd, J = 8.5, 1.8 Hz, 5-H), 7.49 (2 H, d, J = 
6.6 Hz, Ph 2,6-H2), 7.92 (1 H, dd, J = 7.9, 1.7 Hz, 4-H), 8.73 (1 
H, dd, J = 4.9, 1.7 Hz, 6-H); 
13
C NMR (CDCl3)  82.87 (ethyne 
2-C), 98.10 (ethyne 1-C), 106.48 (Ph 1-C), 113.68 (Ph 3,5-C2), 
116.51 (5-C), 121.94 (C≡N), 133.58 (Ph 2,6-C2), 140.65 (3-C), 
145.43 (4-C), 150.12 (6-C), 151.16 (Ph 4-C), 153.27 (2-C); MS 
m/z 242.0693 (M + Na)
+
 (C14H9N3Na requires 242.0694), 
220.0876 (M + H)
+
 (C14H10N3 requires 220.0875). 
4.1.53. 3-Cyano-2-((4-phenylmethoxyphenyl)ethynyl)pyridine 
(25h) 
Compound 21h was treated with 24, CuI, Na ascorbate and 
(Ph3P)2PdCl2 in Pr
i
2NH and THF, as for the synthesis of 25a, to 
give 25h (29%) as an off-white powder: mp 129-132C; IR max 
2215, 2189, 1599, 1506, 1464 cm
-1
; 
1
H NMR (CDCl3)  5.08 (2 
H, s, CH2), 6.98 (2 H, d, J = 9.5 Hz, Ph 3,5-H2) 7.29 (1 H, dd, J = 
7.9, 4.9 Hz, 5-H), 7.31-7.44 (5 H, m, Ph’-H5), 7.62 (2 H, d, J = 
9.5 Hz, Ph 2,6-H2), 7.93 (1 H, dd, J = 1.7 Hz, 7.9 Hz, 4-H), 8.74 
(1 H, dd, J = 4.9, 1.7 Hz, 6-H); 
13
C NMR (CDCl3)  70.06 (CH2), 
85.08 (C≡N), 96.85 (ethyne 2-C), 112.41 (ethyne 1-C), 113.22 
(3-C), 115.11 (Ph 2,6-C2), 116.08 (Ph 1-C), 121.47 (5-C), 127.40 
(Ph’ 3,5-C2), 128.11 (Ph’ 4-C), 128.60 (Ph’ 2,6-C2), 134.24 (Ph 
3,5-C2), 136.26 (Ph’ 1-C), 139.73 (4-C), 146.33 (2-C), 152.73 (6-
C), 160.21 (Ph 4-C); MS m/z 333 (M + Na)
+
, 311.1181 (M + H)
+
 
(C21H15N2O requires 311.1179). 
4.1.54. 3-Cyano-2-(pyridin-4-ylethynyl)pyridine (25l) 
CuI (19.2 mg, 0.10 mmol), (Ph3P)4Pd (57.8 mg, 0.05 mmol), 
24 (184 mg, 1.0 mmol), 21l (103 mg, 1.0 mmol) and Na ascor-
bate (19.8 mg, 0.10 mmol) were placed in a flask, which was 
degassed and filled with Ar. Pr
i
2NH (10 mL) and DMF (10 mL) 
were added. The mixture was stirred at 40C for 10 h. Evaporat-
ion and chromatography (petroleum ether / EtOAc 3:1 → 1:1 → 
1:3) gave 25l (58 mg, 28%) as an ivory-coloured powder: mp 
110-113C; 
1
H NMR (CDCl3)  7.42 (1 H, dd, J = 7.6, 4.9 Hz, 5-
H), 7.52 (2 H, d, J = 4.4 Hz, Py’ 3,5-H2), 8.01 (1 H, dd, J = 7.6, 
1.8 Hz, 4-H), 8.65 (2 H, d, J = 4.7 Hz, Py’ 2,6-H2), 8.82 (1 H, dd, 
J = 4.9, 1.8 Hz, 6-H); 
13
C NMR (CDCl3)  88.71 (ethyne 2-C), 
92.19 (ethyne 1-C), 113.46 (5-C), 115.54 (C≡N), 123.01 (3-C), 
125.84 (Py’ 3,5-C2), 129.03 (Py’ 4-C), 139.85 (4-C), 149.97 (Py’ 
2,6-C2), 150.55 (6-C), 153.91 (2-C); MS m/z 206.0699 (M + H)
+
 
(C13H8N3 requires 206.0719). 
4.1.55. 7-(4-Methylphenyl)pyrano[4,3-b]pyridin-5-one (26b) 
Compound 38 (101.5 mg, 0.5 mmol) was boiled under reflux 
with 37b (252 mg, 1.0 mmol) and Cs2CO3 (163 mg, 0.5 mmol) in 
MeCN (15 mL) for 10 h. The mixture was cooled and poured 
into water (10 mL) and the mixture was extracted with CH2Cl2 (3 
×). The combined extracts were dried. The evaporation residue 
was suspended in petroleum ether (50 mL). The mixture was son-
icated and was filtered. The collected solid was washed (water, 
petroleum ether) to give 26b (110 mg, 93%) as an off-white pow-
der: mp 135-136ºC; 
1
H NMR (CDCl3)  2.41 (3 H, s, Me), 7.16 
(1 H, s, 8-H), 7.28 (2 H, d, J = 8.0 Hz, Ph 3,5-H2), 7.38 (1 H, dd, 
J = 7.9, 4.7 Hz, 3-H), 7.80 (2 H, d, J = 8.3 Hz, Ph 2,6-H2), 8.52 
(1 H, ddd, J = 7.9, 1.7, 0.6 Hz 4-H), 8.92 (1 H, dd, J = 4.7, 1.8 
Hz, 2-H); 
13
C NMR (CDCl3)  21.0 (Me), 102.92 (8-C), 117.0 
(4a-C), 123.0 (3-C), 125.55 (Ph 2,6-C2), 126.0 (Ph 1-C), 129.68 
(Ph 3,5-C2), 137.52 (4-C), 141.0 (4-C), 150.0 (7-C), 156.33 (5-
C), 158.0 (2-C), 162.0 (8a-C); MS m/z 238.0850 (M + Na)
+
 
(C15H12NNaO2 requires 238.0863). 
4.1.56. 7-(4-Methoxyphenyl)pyrano[4,3-b]pyridin-5-one (26c) 
Compound 38 (101.5 mg, was treated with 37c
42
 and Cs2CO3, 
as for the synthesis of 26b, to give 26c (mg, 22%) as an off-white 
powder: mp 169-171ºC (lit.
54
 177-178ºC); 
1
H NMR (CDCl3)  
3.78 (3 H, s, Me), 6.63 (1 H, s, 8-H), 6.88 (2 H, d, J = 9.0 Hz, Ph 
3,5-H2), 7.28 (1 H, dd, J = 7.5, 4.0 Hz, 3-H), 7.76 (2 H, d, J = 8.5 
Hz, Ph 2,6-H2), 8.41 (1 H, d, J = 8.0 Hz, 4-H), 8.81 (1 H, m, 2-
H); 
13
C NMR (CDCl3)  50.43 (Me), 91.46 (Ph 1-C), 101.86 (8-
C), 113.77 (4a-C), 116.51 (Ph 3,5-C2), 122.43 (3-C), 129.49 (Ph 
2,6-C2), 137.67 (4-C), 156.13 (2-C), 157.46 (7-C), 161.77 (8a-C), 
163.66 (5-C); MS (ESI in MeOH, which converts 13c to methyl 
2-(2-(4-methoxyphenyl)-2-oxoethyl)pyridine-3-carboxylate) m/z 
286.1075 (M + H)
+
 (C16H16NO4 requires 286.1082). 
4.1.57. 7-(4-Chlorophenyl)pyrano[4,3-b]pyridin-5-one (26e) 
Compound 38 (101.5 mg, 0.5 mmol) was boiled under reflux 
with 37e (146.5 mg, 0.5 mmol) and Cs2CO3 (163 mg, 0.5 mmol) 
in MeCN (15 mL) for 12 h. The mixture was cooled and poured 
into water. The mixture was extracted (EtOAc, 3 ×). The comb-
ined extracts were washed (brine) and dried. The evaporation res-
idue was washed (petroleum ether) to give 26e (80 mg, 63%) as 
an off-white powder: mp 188-190ºC; 
1
H NMR (CDCl3)  7.13 (1 
H, s, 8-H), 7.36 (1 H, dd, J = 8.0, 5.0 Hz, 3-H), 7.40 (2 H, d, J = 
8.5 Hz, Ph 3,5-H2), 7.78 (2 H, d, J = 8.5 Hz, Ph 2,6-H2), 8.47 (1 
H, d, J = 8.0 Hz, 4-H), 8.87 (1 H, d, J = 4.5 Hz, 2-H); 
13
C NMR 
(CDCl3)  117.02 (8a-C), 123.02 (3-C), 126.91 (Ph 3,5-C2), 
129.34 (Ph 2,6-C2), 129.83 (8-C), 136.98 (Ph 4-C), 137.62 (4-C), 
154.87 (7-C), 156.19 (4a-C), 156.49 (2-C), 161.78 (5-C); MS 
(ESI in MeOH, which converts 26e into methyl 2-(2-(4-chloro-
phenyl)-2-oxoethyl)pyridine-3-carboxylate) m/z 292.0582 (M + 
H)
+
 (C15H13
37
ClNO3 requires 292.0554), 290.0590 (M + H)
+
 
(C15H13
35
ClNO3 requires 290.0578). 
4.1.58. 7-(4-Bromophenyl)pyrano[4,3-b]pyridin-5-one (26f) 
Compound 38 was treated with 37f Cs2CO3, as for the synth-
esis of 26e, to give 26f (93%) as an off-white powder: mp 170-
171ºC; 
1
H NMR (CDCl3)  7.25 (1 H, s, 8-H), 7.47 (1 H, dd, J = 
8.0, 5.0 Hz, 3-H), 7.66 (2 H, d, J = 8.5 Hz, Ph 3,5-H2), 7.81 (2 H, 
d, J = 8.5 Hz, Ph 2,6-H2), 8.57 (1 H, d, J = 8.0 Hz, 4-H), 8.97 (1 
H, d, J = 4.5 Hz, 2-H); 
13
C NMR (CDCl3)  104.01 (8-C), 117.01 
(4a-C), 123.12 (3-C), 125.36 (Ph 4-C), 127.09 (Ph 2,6-C2), 
130.28 (Ph 1-C), 132.30 (Ph 3,5-C2), 137.65 (4-C), 154.85 (8a-
C), 156.27 (3-C), 156.49 (2-C), 161.78 (5-C); MS (ESI in 
MeOH, which converts 26f into methyl 2-(2-(4-bromophenyl)-2-
oxoethyl)pyridine-3-carboxylate) m/z 336.0074 (M + H)
+
 
(C15H13
81
BrNO3 requires 336.0054), 334.0063 (M + H)
+
 
(C15H13
79
BrNO3 requires 334.0073). 
4.1.59. 3-Cyano-4-(phenylethynyl)pyridine (28a) 
4-Bromo-3-cyanopyridine 27 (92 mg, 0.5 mmol) in THF (5 
mL) was added to CuI (9.6 mg, 50 mmol), (Ph3P)4Pd (29 mg, 25 
mmol) and Na ascorbate (9.9 mg, 50 mmol) in Et3N (5 mL) under 
Ar. The mixture was stirred at 40C for 30 min. Phenylethyne 
21a (76.5 mg, 0.75 mmol) was added and the mixture was stirred 
at 40C for 10 h. Evaporation and chromatography (petroleum 
ether / EtOAc 3:1) gave 28a (80 mg, 78%) as an off-white 
powder: mp 74-75°C (lit.
53
 85-87°C); IR max 2222, 2150, 1582, 
1495 (C=N) cm
-1
; 
1
H NMR (CDCl3)  7.39-7.43 (3 H, m, Ph 
3,4,5-H3), 7.45 (1 H, d, J = 5.2 Hz, 5-H), 7.63 (2 H, d, J = 8.2 Hz, 
Ph 2,6-H2), 8.75 (1 H, d, J = 5.2 Hz, 6-H), 8.87 (1 H, s, 2-H); 
13
C 
NMR (CDCl3)  83.50 (ethyne 2-C), 101.29 (ethyne 1-C), 111.74 
(4-C), 115.54 (C≡N), 120.76 (Ph 1-C), 125.06 (5-C), 128.59 (Ph 
3,5-C2), 130.28 (Ph 4-C), 132.38 (Ph 2,6-C2), 134.87 (3-C), 
152.40 (2-C), 152.68 (6-C); MS m/z 227.0569 (M + Na)
+
 
(C14H8N2Na requires 227.0585). 
4.1.60. 3-Cyano-4-(4-methoxyphenylethynyl)pyridine (28c) 
Compound 27 was treated with CuI, (Ph3P)4Pd, Na ascorbate 
and 21c in Et3N and THF, as for the synthesis of 28a, except that 
the chromatographic eluent was petroleum ether / EtOAc (3:1 → 
2:1), to give 28c (68%) as a yellow powder: mp 101-102°C; IR 
max 2218, 2184, 1608, 1581, 1515 cm
-1
; 
1
H NMR (CDCl3)  3.84 
(3 H, s, Me), 6.90 (2 H, d, J = 9.0 Hz, Ph 3,5-H2), 7.43 (1 H, d, J 
= 5.3 Hz, 5-H), 7.57 (2 H, d, J = 9.0 Hz, Ph 2,6-H2), 8,71 (1 H, d, 
J = 8.0, 6-H), 8.84 (1 H, s, 2-H); 
13
C NMR (CDCl3)  55.34 
(CH3), 82.96 (ethyne 1-C), 102.12 (ethyne 2-C), 112.80 (3-C), 
114.07 (C≡N), 114.30 (Ph 3,5-C2), 115.66 (Ph 1-C), 124.72 (5-
C), 134.18 (Ph 2,6-C2), 135.31 (4-C), 152.23 (6-C), 152.63 (2-C), 
161.25 (Ph 4-C); MS m/z 257.0695 (M + Na)
+
 (C15H10N2NaO 
requires 257.0691). 
4.1.61. 3-Cyano-4-(4-trifluoromethylphenylethynyl)pyridine 
(28d) 
Compound 27 was treated with CuI, (Ph3P)4Pd, Na ascorbate 
and 21d in Et3N and THF, as for the synthesis of 28c, to give 28d 
(44%) as a yellow powder: mp 66-68°C; IR max 2232, 1612, 
1568, 1173 cm
-1
; 
1
H NMR (CDCl3)  7.49 (1 H, d, J = 5.2 Hz, 5-
H), 7.74 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 8.58 (1 H, d, J = 5.4 Hz, 
6-H), 8.80 (2 H, d, J = 8.0 Hz, Ph 3,5-H2), 8.91 (1 H, s, 2-H); 
13
C 
NMR (CDCl3)  85.10 (ethyne 2-C), 101.20 (ethyne 1-C), 116.20 
(3-C), 125.15 (5-C), 125.57 (Ph 2,6-C2), 132.63 (Ph 3,5-C2), 
133.00 (4-C), 152.59 (6-C); 
19
F NMR (CDCl3)  -63.07 (CF3); 
MS m/z 273.0636 (M + H)
+
 (C15H8F3N2 requires 273.0634). 
4.1.62. 4-(4-Chlorophenylethynyl)-3-cyanopyridine (28e) 
Compound 27 was treated with CuI, (Ph3P)4Pd, Na ascorbate 
and 21e in Et3N and THF, as for the synthesis of 28c, to give 28e 
(59%) as a yellow powder: mp 79-81°C; IR max 2232, 1569, 724 
cm
-1
; 
1
H NMR (CDCl3)  7.37 (2 H, d, J = 8.4 Hz, Ph 2,6-H2), 
7.47 (1 H, d, J = 5.2 Hz, 5-H), 7.55 (2 H, d, J = 8.4 Hz, Ph 3,5-
H2), 8.75 (1 H, d, J = 5.2 Hz, 6-H), 8.87 (1 H, s, 2-H); 
13
C NMR 
(CDCl3)  99.55 (1-ethyne), 111.70 (3-C), 114.97 (C≡N), 119.28 
(Ph 1-C), 124.96 (2-C), 129.05 (Ph 2,6-C2), 133.57 (Ph 3,5-C2), 
137.80 (Ph 4-C), 152.45 (5-C), 152.70 (6-C); MS m/z 263.0156 
(M + Na)
+
 (C14H7
37
ClN2Na requires 263.0166), 261.0183 (M + 
Na)
+
 (C14H7
35
ClN2Na requires 261.0196). 
4.1.63. 4-(4-Aminophenylethynyl)-4-cyanopyridine (28g) 
Compound 27 was treated with CuI, (Ph3P)4Pd, Na ascorbate 
and 21g in Et3N and THF, as for the synthesis of 28c, to give 28g 
(35%) as an orange powder: mp 155-159°C; IR max 3447, 2218, 
2184, 1631, 1603, 1579 cm
-1
; 
1
H NMR (CDCl3)  4.01 (2 H, br, 
NH2), 6.63 (2 H, d, J = 8.7 Hz, Ph 3,5-H2), 7.40 (1H , d, J = 4.5 
Hz, 5-H), 7.44 (2 H, d, J = 8.7 Hz, Ph 2,6-H2), 8.67 (1 H, d, J = 
5.1 Hz, 6-H), 8.81 (1 H, s, 2-H); 
13
C NMR (CDCl3)  82.71 
(ethyne 1-C), 103.5 (ethyne 2-C), 109.71 (Ph 1-C), 111.22 (3-C), 
114.56 (Ph 3,5-C2), 124.49 (5-C), 134.23 (Ph 2,6-C2), 136.10 (4-
C), 148.55 (Ph 4-C), 152.09 (Ph 4-C), 152.61 (2-C); MS m/z 
242.0681 (M + Na)
+
 (C14H9N3Na requires 242.0694). 
4.1.64. 2-Methyl-8-oxo-6-phenyl-2,7-naphthyridin-2-ium 
iodide (29a) 
MeI (228 mg, 1.5 mmol) was stirred with 11a (55 mg, 0.24 
mmol) in dry DMF (5 mL) for 72 h. The mixture was poured into 
EtOAc (2 mL), followed by petroleum ether (20 mL). The solid 
was collected, washed (petroleum ether) and dried to give 29a 
(10 mg, 11%) as a yellow solid: mp 280-283°C (decomp.); 
1
H 
NMR  4.41 (3 H, s, Me), 7.28 (1 H, s, 4-H), 7.64-7.69 (3 H, m, 
Ph 3,4,5-H3), 7.95 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.20 (1 H, d, J 
= 6.7 Hz, 5-H), 8.82 (1 H, d, J = 6.4 Hz, 6-H), 9.71 (1 H, s, 8-H), 
12.75 (1 H, br, NH); 
13
C NMR  35.77 (Me), 101.16 (4-C), 
120.70 (8a-C), 123.33 (5-C), 127.75 (Ph 2,6-C2), 129.12 (Ph 3,5-
C2), 131.61 (Ph 4-C), 132.12 (Ph 1-C), 143.76 (3-C), 147.25 (6-
C), 147.47 (8-C), 152.06 (1-C), 160.83 (4a-C); MS m/z 237.1038 
(M + H)
+
 (C15H13N2O requires 237.1022). 
4.1.65. 4-Cyano-3-(phenylethynyl)pyridine (35a) 
Compound 34 (91.5 mg, 0.5 mmol) was stirred with (PPh3)4Pd 
(30 mg, 25 mmol), CuI (9.6 mg, 50 mmol) and Na ascorbate (9.9 
mg, 50 mmol) in THF (5 mL) and Pr
i
2NH (5 mL) at 40ºC under 
Ar for 30 min. PhCCH 21a (102 mg, 1.0 mmol) was added and 
the mixture was stirred at 40ºC under Ar for 16 h. Cooling, evap-
oration and chromatography (petroleum ether / EtOAc 4:1 → 
1:3) gave 35a (55 mg, 50%) as a pale buff powder: mp 46-48ºC 
(lit.
53 
49-53ºC); IR max 2222, 2150, 1582 cm
-1
; 
1
H NMR (CDCl3) 
 7.40 (3 H, m, Ph 3,4,5-H3), 7.53 (1 H, d, J = 4.9 Hz, 5-H), 7.62 
(2 H, d, J = 9.6 Hz, Ph 2,6-H2), 8.68 (1 H, d, J = 4.9 Hz, 6-H), 
8.92 (1 H, s, 2-H); 
13
C NMR (CDCl3)  82.54 (1-C), 99.49 (2-C), 
115.57 (C≡N), 121.28 (Ph 1-C), 122.35 (3-C), 124.95 (5-C), 
128.36 (4-C), 128.52 (Ph 3,5-C2), 129.78 (Ph 4-C), 132.09 (Ph 
2,6-C2), 148.40 (6-C), 152.77 (2-C); MS m/z 227.0590 (M + Na)
+
 
(C14H8N2Na requires 227.0580). 
4.1.66. 4-Cyano-3-(4-methylphenylethynyl)pyridine (35b) 
1-Ethynyl-4-methylbenzene 21b was treated with 34, CuI, 
(PPh3)4Pd and Na ascorbate in THF and Pr
i
2NH, as for the syn-
thesis of 35a, except that the chromatographic eluent was petrol-
eum ether / EtOAc (4:1 → 3:2) to give 35b (62%) as a pale buff 
powder: mp 94-96ºC; 
1
H NMR (CDCl3)  2.39 (3 H, s, Me), 7.20 
(2 H, d, J = 8.4 Hz, Ph 3,5-H2), 7.51 (3 H, m, 5-H, Ph 2,6-H2), 
8.65 (1 H, d, J = 5.0 Hz, 6-H), 8.90 (1 H, s, 2-H); 
13
C NMR 
(CDCl3)  21.62 (Me), 100.01 (ethynyl 1-C), 113.20 (C≡N), 
114.90 (ethynyl 2-C), 119.50 (Ph 1-C), 123.50 (4-C), 124.90 (5-
C), 129.15 (Ph 4-C), 129.31 (Ph 3,5-C2), 132.03 (Ph 2,6-C2), 
140.50 (3-C), 148.15 (6-C), 152.02 (2-C); MS m/z 219.0910 (M 
+ H)
+
 (C15H11N2 requires 219.0922). 
4.1.67. 4-Cyano-3-(4-methoxyphenylethynyl)pyridine (35c) 
Compound 21c was treated with 34, (PPh3)4Pd, CuI and Na 
ascorbate in THF and Pr
i
2NH, as for the synthesis of 35b, to give 
35c (72%) as a pale buff powder: mp 96-97ºC; 
1
H NMR (CDCl3) 
 3.85 (3 H, s, Me), 6.91 (2 H, d, J = 8.9 Hz, Ph 3,5-H2), 7.55 (1 
H, d, J = 5.0 Hz, 5-H), 7.56 (2 H , d, J = 8.9 Hz, Ph 2,6-H2), 8.64 
(1 H, d, J = 5.0 Hz, 6-H), 8.88 (1 H, s, 2-H); 
13
C NMR (CDCl3)  
55.35 (Me), 81.72 (ethynyl 1-C), 99.99 (ethynyl 2-C), 113.28 (Ph 
1-C), 114.22 (Ph 3,5-C2), 115.44 (C≡N), 121.92 (4-C), 122.93 (3-
C), 124.87 (5-C), 133.77 (Ph 2,6-C2), 147.92 (6-C), 152.57 (2-C), 
160.81 (Ph 4-C); MS m/z 235.0854 (M + H)
+
 (C15H10N2O 
requires 235.0827). 
4.1.68. 4-Cyano-3-(4-trifluoromethylphenylethynyl)pyridine 
(35d) 
Compound 21d was treated with 34, (PPh3)4Pd, CuI and Na 
ascorbate in THF and Pr
i
2NH, as for the synthesis of 35b, to give 
35d (48%) as a pale orange powder: mp 39-40ºC; 
1
H NMR 
(CDCl3)  7.57 (1 H, d, J = 5.0 Hz, 5-H), 7.67 (2 H, d, J = 8.0 
Hz, Ph 3,5-H2), 7.74 (2 H, d, J = 8.0 Hz, Ph 2,6-H2), 8.73 (1 H, d, 
J = 5.0 Hz, 6-H), 8.95 (1 H, s, 2-H); 
13
C NMR (CDCl3)  84.49 
(ethynyl 2-C), 97.52 (ethynyl 1-C), 115.15 (C≡N), 121.76 (3-C), 
122.21 (4-C), 123.29 (q, J = 298.3 Hz, CF3), 125.05 (5-C), 
125.55 (q, J = 3.6 Hz, Ph 3,5-C2), 131.45 (q, J = 32.8 Hz, Ph 4-
C), 132.39 ( Ph 2,6-C2), 149.13 (6-C), 152.89 (2-C); 
19
F NMR 
(CDCl3)  -63.00 (s, CF3); MS m/z 295.0451 (M + Na)
+
 
(C15H7F3N2Na requires 295.0454). 
4.1.69. 3-(4-Chlorophenylethynyl)-4-cyanopyridine (35e) 
Compound 21e was treated with 34, (PPh3)4Pd, CuI and Na 
ascorbate in THF and Pr
i
2NH, as for the synthesis of 35b, to give 
35e (41%) as a pale buff powder: mp 200-201ºC; 
1
H NMR 
(CDCl3)  7.38 (2 H, d, J = 6.7 Hz, Ph 2,6-H2), 7.53 (1 H, m, 5-
H), 7.56 (2 H, d, J = 6.7 Hz, Ph 3,5-H2), 8.69 (1 H, d, J = 5.5 Hz, 
6-H), 8.91 (1 H, s, 2-H); 
13
C NMR (CDCl3)  92.02 (ethynyl 2-
C), 98.70 (ethynyl 1-C), 113.94 (C≡N), 118.96 (Ph 4-C), 119.21 
(3-C), 123.90 (4-C),124.55 (5-C), 133.28 (Ph 3,5-C2), 133.64 (Ph 
2,6-C2), 135.71 (Ph 1-C), 148.66 (6-C), 152.72 (2-C); MS m/z 
239.0391 (M + H)
+
 (C14H8
35
ClN2 requires 239.0371). 
4.1.70. 7-(4-Methoxyphenyl)-2-methyl-5-oxo-2,6-naphthyrid-
in-2-ium iodide (36c) 
MeI (228 mg, 1.6 mmol) was stirred with 10c (35 mg, 0.13 
mmol) in dry DMF (5 mL) for 36 h. The mixture was poured into 
EtOAc (3 mL). The solid was collected, washed (Me2CO) and 
dried to give 36c (26 mg, 52%) as a yellow solid: mp 263-265C, 
1
H NMR  3.91 (3 H, s, OMe), 4.51 (3 H, br, NMe), 7.15 (1 H, s, 
8-H), 7.18 (2 H, d, J = 8.9 Hz, Ph 3,5-H2), 7.85 (2 H, d, J = 8.9 
Hz, Ph 2,6-H2), 8.63 (1 H, d, J = 6.1 Hz, 4-H), 8.80 (1 H, d, J = 
6.4 Hz, 3-H), 9.59 (1 H, br, NH); 
13
C NMR  48.65 (NMe), 55.51 
(OMe), 98.47 (8-C), 114.51 (Ph 3,5-C2), 124.64 (4-C), 124.71 
(Ph 1-C), 128.85 (Ph 2,6-C2), 131.93 (8a-C), 138.94 (3-C), 
146.18 (7-C), 147.21 (1-C), 160.08 (4a-C), 161.24 (Ph 4-C), 
162.31 (5-C); MS m/z 267.1127 (M)
+
 (C16H15N2O2 requires 
267.1128).  
4.1.71. 3-(4-Methylphenyl)pyrano[3,4-c]pyridin-1-one (40b) 
Compound 39 (101.5 mg, 0.5 mmol) was heated under reflux 
with 37b (252 mg, 1.0 mmol) and Cs2CO3 (163 mg, 0.5 mmol) in 
MeCN (15 mL) for 2 d. The mixture was cooled, poured into 
water and extracted thrice with CH2Cl2. The combined extracts 
were dried. The evaporation residue was suspended in petroleum 
ether (50 mL) and sonicated. The solid was collected and washed 
(water, petroleum ether) to give 40b (38 mg, 32%) as an off-
white powder: mp 120-123ºC; 
1
H NMR (CDCl3)  2.45 (3 H, s, 
Me), 6.90 (1 H, s, 4-H), 7.31 (2 H, d, J = 8.0 Hz, Ph 3,5-H2), 7.33 
(1 H, d, J = 5.5 Hz, 5-H), 7.83 (2 H, d, J = 8.0 Hz, Ph 2,6-H2), 
8.83 (1 H, d, J = 5.5 Hz, 6-H), 9.49 (1 H, s, 8-H); 
13
C NMR 
(CDCl3)  20.5 (Me), 100.0 (4-C), 118.0 (4a-C), 118.5 (5-C), 
121.5 (Ph 1-C), 125.80 (Ph 2,6-C2), 128.9 (Ph 4-C), 129.79 (Ph 
3,5-C2), 130.0 (3-C), 139.5 (8-C), 141.0 (8a-C), 154.0 (6-C), 
159.5 (1-C); MS m/z 238.0851 (M + H)
+
 (C15H12NO2 requires 
238.0863). 
4.1.72. 3-(4-Methoxyphenyl)pyrano[3,4-c]pyridin-1-one (40c) 
Compound 39 (101.5 mg, 0.5 mmol) was heated under reflux 
with 37c (142 mg, 0.5 mmol) and Cs2CO3 (163 mg, 0.5 mmol) in 
MeCN (15 mL) for 2 d. The cooled mixture was poured into 
water and extracted CH2Cl2 (3 ×). The combined extracts were 
washed (brine) and dried. The evaporation residue was washed 
(petroleum ether) to give 40c (16.3 mg, 13%) as an off-white 
powder: mp 185-186ºC; 
1
H NMR (CDCl3)  3.91 ( H, s, Me), 
6.76 (1 H, s, 4-H), 6.96 (2 H, d, J = 8.5 Hz, Ph 3,5-H2), 7.33 (1 
H, d, J = 5.5 Hz, 5-H), 7.88 (2 H, d, J = 8.5 Hz, Ph 2,6-H2), 8.81 
(1 H, d, J = 5.5 Hz, 6-H), 9.47 (1 H, s, 8-H); 
13
C NMR (CDCl3)  
55.49 (Me), 91.51 (4-C), 109.0 (Ph 1-C), 114.48 (Ph 3,5-C2), 
119.0 (5-C), 127.56 (Ph 4-C), 128.23 (Ph 2,6-C2), 131.38 (3-C), 
141.0 (8a-C), 143.0 (6-C), 152.8 (8-C), 163.03 (1-C); MS (ESI in 
MeOH, which converts 40c to methyl 4-(2-(4-methoxyphenyl)-2-
oxoethyl)pyridine-3-carboxylate) m/z 286.1074 (M + H)
+
 
(C16H16NO4 requires 286.1082). 
4.1.73. 3-(4-Bromophenyl)pyrano[3,4-c]pyridin-1-one (40f) 
Compound 39 (101.5 mg, 0.5 mmol) was boiled under reflux 
with 37f (382 mg, 1.0 mmol) and Cs2CO3 (163 mg, 0.5 mmol) in 
MeCN (15 mL) for 3 d. The cooled mixture was poured into 
water and extracted EtOAc (3 ×). The combined extracts were 
washed (brine) and dried. The evaporation residue was washed 
(petroleum ether) to give 40f (10 mg, 7%) as a pale buff gum: 
1
H 
NMR (CDCl3)  6.83 (1 H, s, 4-H), 7.36 (2 H, d, J = 8.5 Hz, Ph 
3,5-H2), 7.69 (2 H, d, J = 8.5 Hz, Ph 2,6-H2), 7.90 (1 H, dd, J = 
8.5, 4.5 Hz, 5-H), 8.73 (1 H, d, J = 4 Hz, 6-H), 9.37 (1 H, s, 8-H); 
13
C NMR (CDCl3)  92.50 (4-C), 118.50 (3-C), 119.03 (4a-C), 
127.35 (Ph 3,5-C2), 129.86 (Ph 1-C), 132.05 (Ph 2,6-C2), 134.50 
(Ph 4-C), 143.46 (8a-C), 152.24 (8-C), 153.91 (6-C), 165.04 (1-
C); MS (ESI in MeOH, which converts 40f into methyl 4-(2-(4-
bromophenyl)-2-oxoethyl)pyridine-3-carboxylate) m/z 336.0011 
(M + H)
+
 (C15H13
81
BrNO3 requires 336.0054), 334.0066 (M + H)
+
 
(C15H13
79
BrNO3 requires 334.0073).  
4.1.74. 3-Phenylpyrano[4,3-c]pyridin-1-one (41a) 
Compound 31 (101.5 mg, 0.5 mmol) was stirred with 37a 
(114 mg, 0.5 mmol), K3PO4 (212 mg, 1.0 mmol) and CuI (10 mg, 
50 mmol) in dry DMF (7 mL) at 100°C under Ar for 6 d. Water 
(7 mL) was added to the cooled mixture. The mixture was extrac-
ted EtOAc (3 ×). The combined extracts were dried. Evaporation 
and chromatography (petroleum ether: EtOAc 5:1 → 3:1) gave 
41a (7.6 mg, 7%) as a yellow powder: mp 171-173ºC (lit.
53
 166-
168ºC); 
1
H NMR (CDCl3)  7.02 (1 H, s, 4-H), 7.48 (3 H, m, Ph 
3,4,5-H3), 7.89 (2 H, m, Ph 2,6-H2), 8.06 (1 H, d, J = 5.2 Hz, 8-
H), 8.76 (1 H, d, J = 5.1 Hz, 7-H), 8.97 (1 H, s, 5-H); 
13
C NMR  
98.52 (4-C), 118.0 (8-C), 125.42 (Ph 2,6-C2), 127.00 (8a-C), 
129.01 (Ph 3,5-C2), 130.64 (Ph 4-C), 131.00 (Ph 1-C), 132.00 (3-
C), 148.44 (7-C), 149.00 (5-C), 151.00 (1-C); MS m/z 224.0708 
(M + H)
+
 (C14H10NO2 requires 224.0712). 
4.1.75. 6-Benzyl-2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyr-
imidin-4-one (47a) 
Compound 46 (1.42 g, 5.0 mmol) was boiled under reflux 
with 45a (600 mg, 5.0 mmol) and NaOMe (from Na (690 mg, 30 
mmol)) in dry MeOH (30 mL) for 10 h, then cooled. The evapor-
ation residue, in water, was sonicated for 5 min. The suspension 
was kept at 2-8°C for 1 h. The solid was collected, washed 
(water, EtOAc) and dried to give 47a (840 mg, 53%) as an off-
white powder: mp 233-235°C; 
1
H NMR  2.70-2.74 (4 H, m, 7,8-
H4), 3.24 (2 H, s, 5-H2), 3.69 (2 H, s, PhCH2N), 7.28-7.37 (5 H, 
m, Ph(Bn) 2,3,4,5,6-H5), 7.47-7.53 (3 H, m, Ph 3,4,5-H3), 8.08 (2 
H, d, J = 7.0 Hz, Ph 2,6-H2); 12.50 (1 H, br, NH); 
13
C NMR  
31.38 (8-C), 49.12 (7-C), 49.45 (5-C), 61.70 (Ph-CH2-N), 117.0 
(4a-C), 127.01 (Ph(Bn) 4-C), 127.46 (Ph 2,6-C2), 128.24 (Ph 2,6-
C2), 128.43 (Ph(Bn) 3,5-H2), 128.78 (Ph(Bn) 2,6-H2), 138.31 (Ph 
1-C), 139.0 (Ph(Bn) Ph 1-C), 145.0 (8a-C), 153.5 (4-C), 159.0 
(2-C); MS m/z 318.1586 (M + H)
+
 (C20H20N3O requires 
318.1601). 
4.1.76. 6-Benzyl-2-(4-methylphenyl)-5,6,7,8-tetrahydropyr-
ido[4,3-d]pyrimidin-4-one (47b) 
Compound 46 was treated with 45b and NaOMe, as for the 
synthesis of 47a, to give 47b (56%) as an off-white powder: mp 
234-235°C; 
1
H NMR  2.37 (3 H, s, Me), 2.69-2.73 (4 H, m, 7,8-
H4), 3.24 (2 H, s, 5-H2), 3.69 (2 H, s, PhCH2N), 7.29-7.31 (3 H, 
m, Ph 4-H, Ar 3,5-H2), 7.34-7.37 (4 H, m, Ph 2,3,5,6-H4), 7.98 (2 
H, d, J = 8.0 Hz, Ar 2,6-H2); 12.50 (1 H, br, NH); 
13
C NMR  
21.0 (Me), 32.0 (8-C), 49.5 (7-C), 49.8 (5-C), 62.0 (PhCH2N), 
125.8 (4a-C), 126.0 (Ph 4-C), 127.41 (Ar 2,6-C2), 128.24 (Ar 3,5-
C2), 128.79 (Ph 2,6-C2), 129.08 (Ph 3,5-C2), 132.0 (Ar 1-C), 
140.0 (Ph 1-C), 142.0 (Ar 4-C), 158.0 (8a-C), 161.5 (4-C), 175.0 
(2-C); MS m/z 685 (2 M + Na)
+
, 663.3494 (2 M + H)
+
 
(C42H43N6O2 requires 663.3447), 354.1592 (M + Na)
+
 
(C21H21N3NaO requires 354.1582), 332.1747 (M + H)
+
 
(C21H22N3O requires 332.1757). 
4.1.77. 6-Benzyl-2-(4-trifluoromethylphenyl)-5,6,7,8-tetra-
hydropyrido[4,3-d]pyrimidin-4-one (47d) 
Compound 46 was treated with 45d and NaOMe, as for the 
synthesis of 47a, to give 47d (60%) as an off-white powder: mp 
234-235°C; 
1
H NMR  2.66-2.73 (4 H, m, 7,8-H4), 3.24 (2 H, s, 
5-H2), 3.70 (2 H, s, PhCH2N), 7.39-7.41 (5 H, m, Ph 2,3,4,5,6-
H5), 7.77 (2 H, d, J = 7.8 Hz, Ar 3,5-H2), 8.44 (2 H, d, J = 7.7 Hz, 
Ar 2,6-H2), 12.50 (1 H, br, NH); 
13
C NMR  31.47 (8-C), 50.14 
(7-C), 50.64 (5-C), 62.19 (PhCH2N), 115.38 (4a-C), 123.36 (q, J 
= 265.0 Hz, CF3), 124.63 (q, J = 3.6 Hz, Ar 2,6-C2), 126.86 (Ph 
4-C), 127.88 (Ph 3,5-C2), 128.15 (Ar 2,6-C2), 128.60 (q, J = 32 
Hz, Ar 4-C), , 128.74 (Ph 2,6-C2), 138.74 (Ph 1-C), 142.81 (Ar1-
C), 156.72 (8a-C), 157.82 (2-C), 169.10 (4-C); 
19
F NMR  -60.77 
(CF3); MS m/z 408 (M + Na)
+
, 386.1493 (M + H)
+
 (C21H19F3N3O 
requires 386.1475). 
4.1.78. 6-Benzyl-2-(4-chlorophenyl)-5,6,7,8-tetrahydropyrido-
[4,3-d]pyrimidin-4-one (47e) 
Compound 46 was treated with 45e and NaOMe, as for the 
synthesis of 47a, to give 47e (58%) as an off-white powder: mp 
211-213°C; 
1
H NMR  2.75-2.78 (4 H, m, 7,8-H4), 3.29 (2 H, s, 
5-H2), 3.74 (2 H, s, PhCH2N), 7.34-7.42 (5 H, m, Ph 2,3,4,5,6-
H5), 7.61 (2 H, d, J = 8.2 Hz, Ar 3,5-H2), 8.15 (2 H, d, J = 7.9 Hz, 
Ar 2,6-H2); 12.65 (1 H, br, NH); 
13
C NMR  32.00 (8-C), 49.80 
(7-C), 49.90 (5-C), 62.00 (PhCH2N), 128.50 (Ar 3,5-C2), 128.79 
(m, Ph 2,3,4,5,6-C5), 129.50 (8a-C), 129.80 (Ar 2,6-C2), 139.00 
(4a-C), 154.00 (1-C); MS m/z 350.1066 (M + H)
+
 
(C20H17
35
ClN3O requires 350.1066). 
4.1.79. 6-Benzyl-2-(4-bromophenyl)-5,6,7,8-tetrahydropyrido-
[4,3-d]pyrimidin-4-one (47f) 
Compound 46 was treated with 45f and NaOMe, as for the 
synthesis of 47a, to give 47f (43%) as an off-white powder: mp 
253-255°C; 
1
H NMR  2.70-2.74 (4 H, m, 7,8-H4), 3.24 (2 H, s, 
5-H2), 3.69 (2 H, s, PhCH2N), 7.28-7.37 (5 H, m, Ph 2,3,4,5,6-
H5), 7.71 (2 H, d, J = 9.0 Hz, Ar 3,5-H2), 8.05 (2 H, d, J = 8.5 Hz, 
Ar 2,6-H2); 12.60 (1 H, br, NH); 
13
C NMR  32.0 (8-C), 49.5 (7-
C), 49.8 (5-C), 62.0 (PhCH2N), 118.7 (4a-C), 127.03 (Ph 4-C), 
128.24 (Ph 2,3,5,6-C4), 128.78 (Ar 2,6-C2), 129.52 (Ar 3,5-C2), 
131.49 (Ar 1-C), 139.0 (Ph 1-C), 156.0 (8a-C), 158.0 (8a-C), 
163.0 (4-C), 163.5 (4-C); MS m/z 398.0665 (M + H)
+
 
(C20H19
81
BrN3O requires 398.0688), 396.0686 (M + H)
+
 
(C20H19
79
BrN3O requires 396.0706). 
4.1.80. 6-Benzyl-2-(4-phenylethynylphenyl)-5,6,7,8-tetra-
hydropyrido[4,3-d]pyrimidin-4(3H)-one (47j) 
NaOMe (259 mg, 4.8 mmol) in dry MeOH (5 mL) was added 
to 46 (216 mg, 0.8 mmol) in dry MeOH (5 mL), followed by 45j 
(177.5 mg, 0.8 mmol) in dry MeOH (5 mL). The mixture was 
stirred at reflux for 16 h. The evaporation residue was 
recrystallised (water) to give 47j (57%) as an off-white powder: 
mp 66-67ºC; 
1
H NMR  2.36-2.66 (2 H, m, 8-H2), 2.86-3.25 (2 
H, m, 7-H2), 3.46-3.63 (2 H, m, 5-H2), 3.68 (2 H, s, PhCH2N), 
7.24-7.38 (4 H, m, Ph’-2,3,5,6-H4), 7.45-7.52 (4 H, m, Ph(Bn)-
2,3,5,6-H4), 7.60-7.69 (2 H, m, Ph’-4H, Ph(Bn) 4-H), 7.80 (2 H, 
d, J = 8.1 Hz, Ph 3,5-H2), 7.96 (2 H, d, J = 8.0 Hz, Ph 2,6-H2); 
13
C NMR  29.73 (8-C), 50.22 (7-C), 51.78 (5-C), 59.94 (Bn-
CH2-N), 87.91 (ethynyl 1-C), 93.27 (ethynyl 2-C), 110.95 (Ph 4-
C), 118.44 (Ph’ 1-C), 121.39 (Bn Ph 1-C), 126.99 (Ph 1-C), 
128.77 (Ph’ 2,3,5,6-H4), 128.86 (Bn Ph 2,3,5,6-H4), 129.53 (Ph’ 
4-C), 131.62 (Bn Ph 4-C), 132.13 (Ph 3,5-C2), 132.60 (Ph 2,6-
C2), 138.33 (8a-C), 165.54 (4-C), 169.11 (2-C); MS m/z 
418.1983 (M + H)
+
 (C28H24N3O requires 418.1919). 
4.1.81. 6-Benzyl-2-(pyridin-4-yl)-5,6,7,8-tetrahydropyrido-
[4,3-d]pyrimidin-4-one (47l) 
Compound 46 was treated with 45l and NaOMe, as for the 
synthesis of 47a, to give 47l (1.27 g, 86%) as an off-white 
powder: mp 298-300°C; 
1
H NMR  2.63 (2 H, m, 8-H2), 2.71 (2 
H, m, 7-H2), 3.23 (2 H, s, 5-H2), 3.69 (2 H, s, PhCH2N), 7.31-
7.42 (5 H, m, Ph 2,3,4,5,6-H5), 8.16 (2 H, d, J = 4.5 Hz, Py 3,5-
H2), 8.58 (2 H, d, J = 4.5 Hz, Py 2,6-H2), 12.50 (1 H, br, NH); 
13
C 
NMR  31.20 (8-C), 50.50 (7-C), 53.70 (5-C), 62.50 (PhCH2N), 
117.60 (8a-C), 121.55 (Py 3,5-C2), 128.13 (Ph 4-C), 128.73 (Ph 
2,3,5,6-C4), 139.5 (Ph 1-C), 148.10 (Py 1-C), 149.80 (Py 2,6-C2), 
157.00 (4a-C), 160.10 (3-C); 182.60 (1-C); MS m/z 341.1374 (M 
+ Na)
+
 (C19H18N4NaO requires 341.1378), 319.1532 (M + H)
+
 
(C19H19N4O requires 319.1559). 
4.2. Protein crystallography 
Protein crystallography experiments were carried out using 
human TNKS-2. The catalytic domain was expressed, purified 
and crystallised as previously reported.
29
 Inhibitors were soaked 
for 48 h into the crystals in a well solution (0.2 M LiSO4, 0.1 M 
Tris-HCl pH 8.5, 24-26% PEG 3350) supplemented with the 
compound (100 µM) and NaCl (250 mM). Before collection of 
data, the crystals were briefly soaked in a well solution supple-
mented with 20% glycerol and flash frozen in liquid N2. 
Data were collected at the Diamond Light Source on beamline 
I04-1. Diffraction data were processed and scaled with the XDS 
package.
55
 The structures were solved using the Difference 
Fourier method, with the starting phases derived from the TNKS-
2 structure (PDB code 3U9H). REFMAC5
56
 was used for refine-
ment and COOT
57
 for manual building of the model. Statistics for 
collection of data and refinement are shown in the Supplementary 
Data. 
Data for structures of 12b and 17a have been deposited at the 
Protein Data Bank with PDB codes 4W5I and 4UX4, respect-
ively. 
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